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ABSTRACT 
EFFECTS OF DIRECT ATP DELIVERY TO ISCHEMIC 
SKELETAL MUSCLE 
Frederico V. Grossi 
October 3, 2007 
The purpose of this dissertation was to demonstrate that a new method of 
direct intracellular energy delivery was effective in maintaining viability of in vitro 
Human Umbilical Vein Endothelial Cells (HUVECs) when exposed to chemical 
ischemia for prolonged periods of time and in preventing in vivo ischemia reperfusion 
injury in a composite tissue transplantation model. Ischemia and reperfusion injury is 
a well recognized phenomenon that occurs in situations like organ transplantation, 
shock, cardiac surgery, etc, where tissues are temporarily deprived of nutrients and 
oxygen for energy production. When exposed to short periods of ischemia, cells 
utilize their stored energy to survive. If ischemia is extended beyond certain limits, 
cellular energy stores become depleted leading to metabolic and structural changes. 
One of the effects of this lack of energy is the malfunctioning of the membrane 
adenosine triphosphate (ATP)-dependent ionic pumps which are ultimately 
responsible for maintaining cellular volume, intracellular pH and ionic homeostasis. 
Thus it is hypotesized that the negative effects of energy depletion on cellular 
homeostasis could be overcome by delivering energy directly into the cell. 
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This method of direct energy delivery into cells is based on fusogenic lipid 
vesicles (FLVs) composed of lipids very similar to those that form the cellular 
membrane. These vesicles are very small and when put in contact with cell 
membranes, rapidly fuse to the cell membrane delivering their content into the cell 
interior. Making use of this phenomenon, the vesicles are loaded with ATP 
magnesium chloride (Mg-ATP) that is delivered directly into the cell, providing it with 
a readily usable form of energy. We hypothesized that, under chemical hypoxia, 
endothelial cell viability could be preserved and the Na+K+-ATPase pump activity 
could be maintained by delivering Mg-ATP directly into the cells. Further, we 
hypothesized that ischemia reperfusion injury due to tissue transplantation could be 
reduced by perfusing tissues ex vivo before reimplantation with a solution containing 
Mg-ATP-Ioaded FL Vs. 
The first two hypotheses were tested in the following manner. First, we 
determined the optimal concentration of Mg-ATP that the FL Vs needed to be loaded 
with to maintain the viability of HUVECs exposed to 4 hours of chemical hypoxia. 
Second, we tested if the Na+K+ ATPase pump activity could be maintained by 
delivering Mg-ATP to HUVECs exposed to chemical hypoxia. The results of these 
experiments demonstrated that direct delivery of Mg-ATP using FLVs was effective 
in maintaining cell viability and Na+K+ ATPase pump activity in cells exposed to 
chemical hypoxia. 
The third hypothesis was tested using a rat hind limb transplantation model. 
Hind limbs were harvested and perfused ex vivo with a preservation solution 
containing Mg-ATP-Ioaded FLVs. After 13 or 21 hours of ischemia limbs, were 
IV 
transplanted to the recipient. Limbs perfused with the Mg-ATP FLV solution 
had a greater survival rate than limbs perfused with control solutions. 
The application of this method of direct cellular energy delivery could have 
great implications in dinical situations where tissues are exposed to long periods of 
ischemia such as transplants or limb amputations. Further investigation is needed to 
optimize this preservation solution to allow its use as routine therapy is these 
situations. 
v 
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CHAPTER 1 
GENERAL BACKGROUND 
Introduction 
Composite tissue transplantation entails the complete detachment of large 
segments of tissue of varied histological types (bone, skin, muscle and nerve) from a 
donor subject with the subsequent transfer and revascularization to the recipient. As 
with other types of transplantation, ischemia and reperfusion (I/R) injury is a 
dominant factor limiting tissue survival. Besides organ transplantation, I/R injury is 
recognized as a serious problem that occurs in a variety of medical procedures 
including, cardiovascular surgery, vascular bypass surgery and reconstructive 
surgery.5 
Ischemia and reperfusion injury is a two step process.5 First, during ischemia, 
tissues become short of oxygen and nutrients and the lack of blood flow leads to 
accumulation of metabolic waste products.3 Second, upon reperfusion, a cascade of 
events is triggered including the production of oxygen radicals and inflammatiory 
mediators leading to endothelial dysfunction and apoptosis.4-7 
Central to I/R injury and associated tissue damage in these procedures is the 
lack of delivery of substrates for energy production to the affected cells during the 
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ischemic period. Cells are unable to produce energy in the form of adenosine 
triphosphate (ATP) resulting in adverse metabolic and structural changes. ATP is 
the main intracellular energy source and is constantly synthesized and metabolized 
in the body to maintain life. Virtually all cell processes are driven by the energy 
released when ATP is hydrolysed to form adenosine diphosphate (ADP) and 
inorganic phosphate. For most cells, the majority of ATP is generated in the 
mitochondria. The balance between energy consuming and Bnergy producing 
reactions in a cell is carefully maintained, and the central metabolic ATP is kept at 
an almost constant level in spite of a VBry short turnover time. Cells do not use food 
nutrients as their energy supply. They almost exclusively use ATP, which is the 
essential link between energy production and energy utilization.8-1o 
To overcome the lack of cellular energy during ischemia, direct intravascular 
infusion of ATP to the ischemic tissues might be a rational approach. However, 
sufficient intracellular concentrations of ATP cannot be achieved because ATP does 
not diffuse across the cell membrane. Furthermore, ATP has a short half life of less 
than 5 min. 
In Dr. Ehringer's laboratory, a highly efficient fusogBnic lipid vesicle (FLV) that 
delivers its content into cells by fusing with the cell membrane was developed. By 
loading these FLVs with adenosine triphosphate magnesium chloride (Mg-ATP), 
exogenous energy (in the form of Mg-ATP) can be delivered into cells. This 
dissertation investigates the feasibility of protecting cells and composite tissues 
(skin, muscle, bone and nerve) from I/R injury by delivering exogenous Mg-ATP 
using FL Vs infused intravascularly. 
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Cellular Energy 
ATP is the main intracellular energy source and is constantly synthesized and 
metabolized in the body to maintain life. Synthesis of proteins, fats and 
carbohydrates necessary for cell integrity, normal activity and function are 
dependent on ATP availability. All these cell processes are driven by the energy 
released when ATP is hydrolyzed. The majority of ATP is generated in the 
mitochondria. The balance between energy consuming and energy producing 
reactions in a cell is carefully maintained, and the central metabolic ATP is kept at 
an almost constant level in spite of a very short turnover time 11. ATP is a purine 
nucleotide containing two high-energy phosphate bonds. When these bonds are 
hydrolyzed, free energy is liberated12-14 . The synthesis of ATP by the respiring 
mitochondria requires inorganic phosphate, magnesium, substrate (usually glucose), 
ADP and the presence of oxygen 15. Eukaryotic cells, with the help of mitochondria, 
can use oxygen as the terminal electron acceptor during oxidative phosphorylation. 
The participation of oxygen in the ener~~y transformation process allows large 
amounts of free energy to be liberated during metabolism. This can be 
demonstrated most simply by comparing the yield of ATP from oxidation of glucose 
under anaerobic versus aerobic conditions. Anaerobic glycolysis to lactate (Figure 
1) produces 2 moles of ATP per mole of glucose whereas aerobic glycolysis to 
carbon dioxide and water though the Kmbs cycle and oxidative phosphorylation 
delivers 36-38 moles of ATp16,17 (Figure 2). Therefore, adequate supply of oxygen 
enhances ATP yield by 18-19 fold. ThE~ importance of oxygen for ATP production in 
humans has been confirmed in vivo. In patients with chronic circulatory and/or 
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respiratory insufficiency, mitochondrial ATP levels were only one-half of the levels 
found in normal patients 18. Magnesium plays a critical role in key enzymatic 
reactions for both the aerobic and anaerobic glycolysis 19,20. It has been known since 
the discovery of the Na+,K+ pump that magnesium is required for enzymatic 
activity21. The uptake and accumulation of magnesium by the mitochrondria is 
associated with enhanced uptake of phosphate and proton extrusion22. Also, most 
enzymes involved in the biochemistry of nucleic acids require a divalent metal ion 
cofactor to promote activity, and magnesium is with rare exceptions the metal ion of 
choice23. 
I/R injury 
IIR injury is recognized as a serious problem that occurs in a variety of medical 
procedures including thrombolytic therapy, organ transplantatiion, vascular bypass 
surgery, trauma and reconstructive sun~ery5. I/R injury is a two step process. 
During ischemia, depletion of cellular energy storage, loss of cellular homeostasis 
and accumulation of metabolites lead to cell damage that can be reversible 
depending on the duration of the ischemia.3 During reperfusion, further damage is 
produced though the production of reactive oxygen species, inflammatory mediators 
and chemotactic factors.4-7 Figure 3 summarizes the most typical events during I/R 
injury. 
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Figure 1. Anaerobic Glycolysis 
Glucose gets broken down to pyruvate. Then pyruvate is converted to 
lactate through the Cory cycle (Lactic acid fermentation). Through this 
pathway glucose is not completely broken down and it does not release 
all its stored energy. It only produces 2 moles of ATP per mole of 
glucose. Copyright Pearson Education, Inc. 
Available at: 
http://scidiv.bcc.ctc.edu/gb/Biol%20130/Lectures/Metabolism.htm 
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Figure 2. Cellular Respiration 
Pyruvate is converted to AcylCoA , which then goes through the Krebs 
cycle producing NADH and FADH2. These two compounds then go 
through the electron transport chain which releases their energy to 
produce ATP. Though this pathway up to 38 moles of ATP can be 
produced for every mole of glucose. 
Copyright Pearson Education, Inc. Available at: 
http://scidiv.bcc.ctc.edu/gb/Biol%20130/Lectures/Metabolism.htm 
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Changes occurring during ischemia 
Ischemia is an absolute or relative shortage of the blood supply to an organ. 
Insufficient blood supply causes tissue to become hypoxic, or, if no oxygen is 
supplied at all, anoxic. Prolonged hypoxia or anoxia results in multiple cellular 
metabolic and structural changes (Table 1). Although the tolerance to ischemia 
varies with tissue types and adaptive mechanisms, cell dama!~e inevitably occurs 
after extended periods of anoxia. Decrease in cellular oxidative phosphorylation 
results in a failure to resynthesize energy rich-phosphates including ATP. Such 
energy depletion leads to an alteration of the function of membrane ATP-dependent 
ionic pumps, which favor the efflux of potassium and influx of sodium, calcium and 
water into the cell provoking cell swelling, cytoskeletal disorganization and further 
membrane rupture and necrotic cell death3 (Figure 4). Adenine nucleotide 
catabolism during ischemia results in the accumulation of hypoxanthine which can 
be further converted into reactive oxygen species (ROS) when oxygen is 
reintroduced upon reperfusion7. Within the endothelium, the production of certain 
bioactive agents (prostacyclin, nitric oxide) will be diminished, while the production of 
others (endothelin, thromboxane A2) will be augmented6. Also, in endothelial cells, 
certain genes such as adhesion molecules P-selectin and ICAM-1 are induced, while 
others like cNOS and thrombomodulin are suppressed. Upon reperfusion, many of 
these changes are exacerbated by reoxygenation and more severe damage occurs. 
9 
Figure 3. The sequence of events occurring during ischemia and 
reperfusion. Khalil et al Plast. Reconstr. Surg. 117: 1024, 2006. 4 
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Table 1. Summary of the multiple cellular metabolic and structural 
changes that occur during ischemia or hypoxia. 
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Effects of Ischemia or Hypoxia on Cells 
Cellular acidosis 
Altered membrane potential 
Altered ion distribution (increased intracellular Ca++/Na+ ratio) 
Cellular swelling 
Cytoskeleton disorganization 
Increased hypoxanthine 
Decreased A TP 
Decreased phosphocreatine 
Decreased glutathione 
Stabilization and nuclear translocation of hypoxia-inducible factor 1 (HIF-1) 
Increased leukocyte adhesion molecule expression 
13 
Figure 4. ATP turnover of cells as a function of time exposure to 
anoxia or hypothermia. When the balance between ATP supply and 
ATP demand is lost, a cascade of events is triggered that leads to cell 
death by necrosis. Boutilier, R. G. J Exp Bio/2001;204:3171-3181 3 
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Alteration of ionic transport systems 
The concentration of Na + is typically 10-20 times higher outside cells than 
inside, whereas the reverse is true for K+. The maintenance of this differential 
concentration has several biological implications. The Na+ gradient provides an 
energy source for a set of Na+-linked transporters (ie: Na+Cr cotranporter, Na+ Ca2+ 
exchanger)24 and is involved in several homeostatic functions including the 
regulation of cell volume, intracellular pH and intracellular Ca:2+ concentration24,25. It 
is well known that the Na+,K+ -ATPase pump is responsible for the maintenance of 
the Na+ gradient by the coupled movement of K+ and Na+ into and out of the cell 
respectively. The pump expels 3 Na+ in exchange for 2 K+ generating an 
electrochemical gradient with the intracellular space being low in Na + and 
electronegative. This electrochemical gradient creates a "sodium-motive forcI3", 
which drives Na+ back into the ceIl22,26. The pump activity requires ATP. It has been 
estimated that the Na+,K+ -ATPase pumps consume -33% of the total energy (ATP) 
used by a typical animal cell. Blockade of the pump with ouabain inhibits its activity 
and prevents cells from maintaining their Na + /K+ balance, which will disrupt cell 
homeostasis22 . Similarly, when cells are deprived from oxygEin for oxidative 
phosphorylation, intracellular levels of ATP gradually dwindle, and cause a decrease 
in ATPase activity, which also disrupts cell Na+/K+ balance and membrane poltential. 
Imahashi et al.27 showed in the rat heart that intracellular Na+ accumulated during 
ischemia and that the amount of accumulated Na + at the end of ischemia was 
correlated with the duration of the ischemia. They also showed that the 
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accumulation of Na+ during ischemia is a major determinant of the severity of the I/R 
injury. In another study using a potassium cyanide (KCN) poisoned rat heart, 
Kupriyanov et al.,28 showed that KCN infusion caused a decrease in 
phosphocreatinine and ATP and an increase in phosphatidylinositol (PI) and Na+. 
This suggests that inhibition of Na+,K+ -ATPase pump by PI is responsible for 
intracellular Na+ accumulation, whereas loss of K+ is associated with inhibition of the 
Na+"K+ -ATPase pump as well as an activation of ATP-sensitive K+ channels and the 
K+ -lactate cotransporter. Na + accumulation during ischemia induces contractile 
dysfunction, has a deleterious effect on energy metabolism 2SI,30 and results in Ca2+ 
overload during the initial phase of reperfusion31 -33. 
Cell Death and IIR Injury 
There are two ways in which cells die, either by injurious agents or by suicide 
(program cell death). When injury occurs from mechanical or toxic chemical 
exposure, cells and their organelles loose their ability to control passage of ions and 
watE!r. This process is called cell necrosis. As cells die, the cellular content starts to 
leak out and promote an inflammatory response in surrounding tissues. To the 
contrary, when cells are induced to undergo apoptosis, they shrink, the mitochondria 
break down and release cytochrome c. The cells develop bubble-like blebs 011 the 
surface, and the DNA degrades, breaking into small membrane-wrapped fragments. 
The intracellular machinery responsible for apoptosis depends on a family of 
proteases called caspases. Caspases have a cysteine at their active site and cleave 
their target at specific aspartic acids,22 During this process, the phospholipid 
phosphatidylserine on the membrane of fragments binds to receptors on phaglocytic 
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cells, which engulf and digest the cellular debris. Phagocytic cells also inhibit the 
inflammatory response by secreting anti-inflammatory cytokines34.35. 
In skeletal muscle, evidence of DNA fragmentation using propidium iodide has 
been sparse and controversiaI36-46. In a rat hind limb model of I/R injury, recent 
studies have reported that skeletal muscle is resistant to reactive oxygen species 
(ROS) induced apoptosis.36.44 Furthermore, skeletal muscle appears to possess an 
inherent resistance to apoptosis but this is still a subject of discussion.47-5o Some 
have found that thecaspase inhibitors FLiCE/caspase-B inhibitory protein (FLlP)48 
and apoptosis repressor with card (ARC)49 are highly expressed in skeletal muscle 
relative to other tissues, providing it with certain resistance to apoptosis. Moreover, 
caspase-3 protein has been reported to be absent in skeletal muscle,5o and 
evidence that human skeletal muscle cytosol lacks Apaf-1 ,47 suggests that skl9letal 
muscle is resistant to apoptosis. On the other hand, recent reports indicate that 
certain situations like denervation,39 aging,40 dystrophy,43 and mechanical 
ventilation51 induced disuse are associated with a loss of muscle nuclei through an 
apoptosis-like process.37.41.42 This "myonuclear apoptosis" can occur without 
complete cell death in multinucleated cells38.41.52 and it seems to be a strategy to 
maintain the nuclei/fiber area ratio constant.41 Conversely, satellite cells are k:nown 
to undergo apoptosis,5o.53.54 and in some muscle studies, apoptotic satellite cells 
may have been mistakenly identified as apoptotic mature myocytes. 
Cell death in I/R injury is usually associated with the generation of ROS during 
reperfusion, and the release of cytochrome c into the cytoplasm55.56. ROS have 
been reported to directly damage the mitochondrial membrane causing what is 
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known as mitochondrial permeability transition (MPT). MPT can occur temporarily 
but can rapidly become irreversible resulting in loss of mitochondrial homeostasis 
and producing dangerous mitochondrial swelling57 . Another mechanism that has 
been implicated in ROS induced cytochrome c release involves the action of the 
proapoptotic protein Bax (of the BcI-2 family). It has been reported that Bax under 
oxidative stress conditions is overexpressed and is translocated from the cytosol to 
the mitochondrial membrane inducing cytochrome c release into the cytosoI58-6o. 
Once cytochrome c is released into the cytosol (by MPT or Bax translocation), it 
aggregates with apoptotic protease-activating factor-1 (Apaf-1), procaspase-9I, and 
ATP. The resulting complex (apoptosome) activates caspase-9, which in turn 
activates a series of caspases ultimately activating caspase-3. As ROS are 
generated during reperfusion and cytochrome c leaks out into the cytoplasm, the 
capacity of the electron transport system to generate ATP in the mitochondria is 
compromised. If the process is not quickly reversed, the cell's energy resources 
dwindle, and cell death by necrosis occurs61 -65. Figure 5 summarizes mitochondrial 
factor-mediated apoptosis and necrosis induced by oxidative stress. 
I/R Injury and the Microcirculation 
The molecular and biochemical changes that occur in the microvascular bed 
following I/R injury are typical of an inflammatory response. This response is 
comprised of a series of complex reactions that occur in the endothelium and 
adjacent tissues. The most severe acute inflammatory response induced by IIR 
injury is triggered by the reintroduction of blood and oxygen to ischemic tissues5,66,67 
19 
Figure 5. Apoptotic and necrotic pathways after oxidative stress of 
mitochondria. Release of cytochrome c from the mitochondria leads to 
decreased production of ATP, and in skeletal muscle cells primarily 
undergo the necrotic pathway only. (ROS= reactive oxygen species; 
AIF= apoptosis-inducing factor; MPT= mitochondrial permeability 
transition; Apaf-1 =apoptotic protease-activating factor-1). 
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During reperfusion, reoxygenation leads to over production of ROS. The major 
sources of ROS are the xanthine oxidase system and the nicotinamide adenine 
dinucleotide phosphate (NADPH) system4 (Figure 6). ROS can induce cell death by 
disrupting cellular integrity and initiating apoptosis68-72 . 
Leukocyte recruitment and migration into the tissue are key to the development 
of I/R injury. Leukocytes marginate and adhere to the endothelium. Mast cell 
histamine release facilitates leukocyte migration into the perivascular space through 
gaps opened between venular endothelial cells or by migrating through endothelial 
cells73,74. Once leukocytes have migrated into the tissue, they can cause further 
damage by secreting proteolitic enzymes or production of free radicals.5 
Microcirculation studies in skeletal muscle of humans and animals that 
examined ultrastructure changes of microvessels during and following 3 hours of 
ischemia were remarkably similar75 . The first noticeable changes observed occurred 
in capillary endothelial cells. The endothelial cell membranes developed finger-like 
protrusions into the capillary lumen and invaginations into the cytosol. As the 
ischemia progressed, there was complete disjunction of adjacent endothelial cells 
resulting in extremely broad gaps in the endothelium. Edema of endothelial cells 
gradually progressed in some but not all cells creating an uneven surface. 
Leukocytes and platelets were rare. The primary finding consisted of erythrocytes 
tightly wedged in the capillary lumen. In animal studies only, after more than 4 hours 
of ischemia, cellular interactions became apparent and these were erythrocytic, 
thrombotic and leukocytic75 . The capillaries and venules were filled with tightly 
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wedged erythrocytes so as to appear fused. During early reperfusion the 
erythrocytes were compacted into rouleau that appeared to deform and rupture the 
endothelial surface. Large inter-endothelial gaps resulted from focal disintegration of 
the endothelial cytoplasm. Thrombotic interactions became particularly prominent 
and were characterized by the occurrence of intraluminal masses of platelets in 
post-capillary venules. The endothelium of such vessels was lost over long 
distances, with intertwining platelets closing the defects. Leukocyte interactions 
were observed in larger venules and small veins with increased white cell adherence 
to the endothelial surface and migration to the extravascular space. In capillaries, 
they observed leukocytes, lymphocytes and monocytes plugging the lumena. l5 
Pathophysiology of I/R injury in Skeletal Muscle 
The re-establishment of blood flow to ischemic muscle produces what is known 
as the reperfusion syndrome. It was first established in patients in whom blood flow 
had been restored to ischemic extremities, but also has been reported following 
heart surgery, organ transplantation and revascularization of ischemic intestine?6. 
The syndrome has a local component that results in an increase of the regional 
damage, and a systemic component that can result in the secondary failure of 
organs and tissues remote from the ischemic area. The tolerance of tissues for 
ischemia varies with the nature of the tissue. In extremities, muscle appears Io be 
tolerant for up to 4 hours, nerve changes remain reversible up to 8 hours, fat up to 
13 hours, skin up to 24 hours and bone up to 4 days?? 
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Figure 6. Sources and fate of superoxide radicals. 
Khalil et al Plast. Reconstr. Surg. 117: 1024, 2006. 4 
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It is widely accepted that the duration of ischemia correlates directly with the severity 
of the injury. However, it has been difficult in muscle to distinguish when muscle 
cells die because gross and microscopic changes are minimal for many hours 
following muscle death. Using a tourniquet ischemia limb model and a 
spectrophotometric technique to analyze muscle damage, Belkin et al.31 detel"mined 
that significant muscle injury occurred after 3 hours of ischemia and that after 4, 5 
and 6 hours, the injury was severe. 
Studies in ischemic muscle have demonstrated a close correlation betwHen 
myonecrosis and depletion of ATP. Hayes et al.78 reported that during ischemia, 
myocyte glycogen and creatine phosphate are preferentially depleted over AlP, and 
that until ATP was depleted, little muscle necrosis occurred. In a similar study, 
Labbe et al.79 reported that the extent of necrosis in muscle after 3, 4 and 5 hours of 
warm ischemia was 2, 30, and 90%, respectively. 
Microvascular Dysfunction after I/R 
It is now well established that I/R results in severe dysfunction of the affected 
endothelium5. This is the result of a combination of factors, which appear to be 
centered around a reduction in nitric oxide (NO) release80 and an increased 
expression of vascular adhesion factors. NO is a diatomic free radical, which is 
synthesized from L-arginine by a family of enzymes, termed NO synthases. The 
presence of NO in tissues has both direct and indirect effects. Direct effects are 
mediated by the direct interaction of NO with specific biological molecules. In 
contrast, indirect effects are mediated by reactive nitrogen oxide species formed 
from the reaction of NO either with oxygen to form dinitrogen trioxide (N20 3) or 
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superoxide radical to form peroxynitrite (ONOO-)5,81. Nitric oxide can act in a tissue-
protective manner through the physiological regulation of vascular tone, inhibition of 
platelet aggregation, attenuation of leukocyte adherence to the endothelium, 
scavenging oxygen-free radicals, maintenance of normal vascular permeabiliRy, 
inhibition of smooth muscle proliferation, immune defenses, and stimulation of 
endothelial cell regeneration5,82 oo84. The mechanisms responsible for the inhibition of 
NO production are still unclear. One of the mechanisms postulated is a 
physiological imbalance that favors O2- accumulation over NO during the early 
phase of reperfusion. Oxygen radical accumulation is the result of a variety of 
factors, including a substrate-initiated burst in xanthine oxidase activity and an 
inhibition of endogenous superoxide dismutase (SOD) and catalase activity. 
Consequently, the accumulation of NO will be limited and its beneficial actions, 
including vasodilation, prevented85-88. This will lead to dysfunction of the 
endothelium manifested as a lack of vasodilation contributing to a "no-reflow 
phenomenon" and a strong tendency for leukocytes to adhere to vascular 
endothelium. 18,89,9o and for platelets to aggregate82. Furthermore, in the absence of 
NO, O2- undergoes spontaneous dismutation to form H202, which can promotl9 
activation of phospholipase A2, result in the generation of inflammatory mediators 
and activate NF-KB, a primary regulator of cytokine and adhesion molecule gene 
expression5. Another mechanism to explain the inhibition of NO production is 
offered by recent in vitro reports that suggest that NADPH levels fall during 
ischemia91 . NADPH is the reduced form of NADP+ and is produced inside the 
mitochondria in the so-called "forward reaction,,92. A lack of NADPH will inhibit NO 
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synthesis by depriving NO synthase of energy. It has been well-established in vitro 
that NADPH levels can be increased by artificially supplementing ATP to cells and 
thus reduce mitochondrial pyridine nucleotides in a process called reversed electron 
transport93.94. In addition to this effect, the reduction of mitochondrial pyridine 
nucleotides could prevent mitochondria-mediated apoptosis by keeping the 
structural integrity of mitochondria intact.95-99 
Finally, NADPH could participate directly in preventing I/R injury by eliminating 
hydroperoxides through the glutathione peroxidase/glutathione reductase and 
thioredoxin peroxidase/thioredoxin reductase enzyme systems95,96,100,101. 
Exogenous A TP as an Energy Source 
Numerous methods have been tried in the past to avert the grave consequence 
of energy depletion with limited success31 ,102-108. Although a few other molecules 
can serve as a source of energy in the cell, such as creatine phosphate and other 
nucleotide phosphates (e.g., GTP, CTP, and UTP), their production is also ultimately 
dependent on the supply of ATp109-111. Direct infusion of ATP or its precursors into 
tissues or organs is a logical approach that would provide an immediate ener~lY 
supply. However, this approach has never yielded noteworthy results with in vivo 
experiments because the unique structure of the cell membrane prevents freB 
diffusion of many substances including ATP. By serving as a selective barrier to the 
passage of molecules, the cell membrane determines the composition of the 
cytoplasm and the identity of the cell. The basic structure of the membrane is the 
phospholipid bilayer, which is pE~rmeable only to gases, small hydrophobic 
molecules, and to small polar uncharged molecules such as ethanol. Even water 
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has a low permeability to many lipid bilayer structures. Most cells have aquaporins 
(protein channels) imbedded in the cell membrane to allow water to move in and out 
of cells112 • Larger polar molecules (such as glucose) and charged molecules (such 
as H+, Na+, cr, Ca++, and amino acids) are not permeable unless they have 
channels or transporters. The highly charged high-energy phosphates like ATP or 
its many precursors do not pass through the cell membrane and therefore, 
extracellular sources of ATP cannot be used for cell metabolism. 
Multilammellar Vesicles (Liposomes) as Drug Delivery VehiclE!S 
The use of liposomes to deliver drugs such as antibiotics and anticancer 
agents has been in practice for years 113-119. Liposomes can be filled with a variety of 
agents and, because of their similarity to cell membranes, are not toxic. They also 
protect their loads from being diluted or degraded in the blood. As a result, when the 
liposomes reach diseased tissues, they deliver concentrated doses of the agent they 
carry. Liposomes are made of phospholipids (amphipathic molecules) that fmm 
closed, fluid-filled spheres when mixed in water. As a liposome forms, any water-
soluble molecules that are in the solution are encapsulated in the aqueous space in 
the interior of the sphere, whereas any lipid-soluble molecules present in the solution 
are incorporated into the lipid bilayer. 
The interactions between liposomes and cell membranes have several forms 
(Figure 7).2 Liposomes can adsorb to almost any cell type. Once they have 
adsorbed, the spheres may be endocytosed by some cells. Adsorbed liposomes 
can also exchange lipids with cell membranes and may at times be able to fuse with 
cells. When fusion takes place, the liposomal membrane is integrated into the cell 
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membrane and the aqueous contents of the liposome merge with the fluid in the 
cytosol. Because individual liposomes were shown to be capable of carrying 
thousands of drug molecules, this delivery technique becomes very efficient for 
some impermeable substances such as ATP. ATP delivery to tissues using 
liposomes has been tried in a small number of studies85,120-129. In a set of studies 
that used isolated perfused rat livers, Neveux et a1. 120,127 studied the effects of 
preserving livers with liposomally entrapped ATP in University of Wisconsin (UW) 
solution. They found that rat livers preserved in this cocktail for 18 hours at 4°C 
attenuated a decrease in hepatic ATP content, and during reperfusion, proteolysis 
was decreased and was associated with an increase in cell volume. The authors 
concluded that liposomally entrapped ATP represents an effective means to improve 
liver graft energy state and function. Also in a liver study that used a hypovolemic 
shock rat model, Konno et al. 126 studied the effect of liposomally entrapped ATP on 
the liver during shock and reperfusion. They found that administration of liposomally 
entrapped ATP significantly improved hepatic blood flow, reduced hepatic enzyme 
release, and produced the fastest hepatic ATP recovery. The authors concluded 
that hepatic blood flow during and after hypovolemic shock was enhanced by the 
improved energy level and metabolism of hepatocytes. In a third study, Puisieux et 
al. 128 using intra-carotid administration of ATP-entrapped liposomes reported a 
significant increase in the number of brain ischemic events tolerated by rats before 
the first irreversible electro-corticogram (ECoG) silence occurred and before death. 
The authors also studied the ability of their liposomes (loaded with 
carboxyfluorescein) to cross the blood-brain barrier in rat brain slices. 
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Figure 7. Liposomes interact with cells in four distinct ways: a) 
absorption, b) endocytosis, c) lipid exchange, d) fusion. 
Ostra et al. Scientific American, 256:102-111, 1987 2 
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They found areas of punctuated fluorescence in the parenchyma and concluded that 
under hypoxic conditions tight junctions were opened and allowed liposomes Ito 
pass. Verma et aI123-125,129, in a set of myocardial ischemia studies, showed a 
reduction in the irreversible damaged area 123 and a substantially improved functional 
recoveri 24,125 after 30 min of total ischemia and 3 hours of reperfusion by perfusing 
the hearts with ATP-Ioaded liposomes before the ischemic insult. They also showed 
that the liposomes can cross the wall of myocardial capillaries 125 and that they can 
be targeted by attaching monoclonal anti-bodies against the target tissue to their 
surface.124 Using a sepsis model, Han et al. 122 showed that endothelial cells can be 
protected from energy failure when treated with liposome encapsulated ATP. In the 
above studies, none of the authors presented data that would indicate that their 
liposomes were very fusogenic. Therefore, it is not clear how their liposomes would 
exert a beneficial effect. In a study by Arakawa et a1.85, ATP-entrapped liposomes 
were tested in vitro and were proposed to be used as a slow release system to 
rescue the ischemic retina. Though, no animal experiments were performed, the 
authors did report the slow rate of release (35% of entrapped drug within 90 hours) 
of their liposomes. A similar in vitro study using ATP-entrapped liposomes was 
performed by Xu et al. 129 In this study the authors reported that liposomal release of 
ATP was a mere 10% after 50 days. 
The two most significant problems with all of the above studies are that the 
authors did not attempt to modify the phospholipid formulation of liposomes to 
increase fusogenicity to cell membranes, and that the diameter of liposomes used 
were too large to escape the vasculature. Therefore, it is not clear how their 
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liposomes could deliver significant amounts of ATP to meet metabolic demand of 
cells in the vasculature as well as in the parenchyma. As reported by some of the 
studies above, liposome release of ATP was very slow, and if adsorption by the cell 
membrane does occur, ATP delivery to the cytosol will not be automatic. 
Unencapsulated drugs typically diffuse through pores in the microvasculature, but 
standard liposomes are too large to pass through the endothelial barrier of most 
tissues, and therefore, small liposomes would need to be engineered to escape the 
intravascular space to reach cells in the parenchyma. 
Small Fusogenic Lipid Vesicles (FLVs) as Drug Delivery Vehicles 
Lipid vesicles can be made in a variety of layers and sizes (Figure. 8). 
Multilamellar vesicles have multiple layers of lipid and water, whereas large 
unilamellar vesicles and small unilamellar vesicles have a single phospholipid 
bilayer. To engineer small FLVs that effectively deliver agents, the vesicles must not 
fuse readily with each other and must not be so unstable as to leak their internal 
content. To enhance vesicle membrane fusion, the charge of the phospholipid head 
group can be manipulated to create dissimilar regions in the lipid layer and the 
vesicle's radius of curvature can be adjusted to provide different levels of stored 
kinetic energy. Liposomes or multilamellar vesicles are not readily fusogenic, mainly 
because the stored energy of the vesicle's radius of curvature is minimal. However, 
small unilamellar vesicles, which have a very tight radius of curvature, are very 
fusogenic. It has been reported that changes in lipid composition can dramatically 
alter vesicle-cell membrane fusion rates. Also by tightening the vesicle's radius of 
curvature the fusion rate can be further increased. 13o 
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Figure 8. Different types of lipid vesicles. Lipid vesicles can be made 
into multilamellar vesicles, small unilamellar vesicles (SUV), or large 
unilamellar vesicles (LUV). From Avanti Lipids, Inc. 
A vailable at: http://www.avantilipids.com/PreparationOfUposomes.html 
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FUNDAMENTAL QUESTIONS 
Phenomenon: 
I/R injury is recognized as a serious problem that occurs in a variety of medical 
procedures including, cardiovascular surgery, vascular bypass surgery 
transplantation, and reconstructive surgery. During ischemia, intracellular ATP 
levels decline leading to loss of cell homeostasis and cell death. This can be 
prevented by delivering Mg-ATP directly into the cells with the aid of FLVs. 
Questions: 
This dissertation addresses two questions: 
1. Can the Na+,K+ -ATPase pump activity be maintained by supplementin!~ 
hypoxic human endothelial cells with direct delivery of exogenous Mg-ATP? 
2. Can the vascular endothelium of ischemic skeletal muscle in rat hind Ilimbs 
be preserved by direct delivery of exogenous Mg-ATP? 
Hypothesis # 1 
Delivery of exogenous Mg-ATP using FL Vs can preserve endothelial cell viability 
during chemical hypoxia. 
To test hypothesis #1, we designed two in vitro experiments that used K+ 
cyanide (KCN) to induce chemical hypoxia. Experiment 'I determined the optimal 
dose of Mg-ATP that preserves HUVEC viability after 4 hours of chemical hypoxia. 
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Experiment 2 determined the effect of varying FLV numbHrs on HUVEC viability after 
4 hours of chemical hypoxia when the Mg-ATP levels were held constant. 
Hypothesis # 2 
Direct delivery of exogenous Mg-ATP main1tains Na+,K+ -ATPase pump function 
following chemical hypoxia 
To test hypothesis #2, experiment #3 was designed to determined the ability of 
Mg-ATP-Ioaded FLVs to maintain Na+,K+ -ATPase pump function during chemical 
hypoxia. Cell uptake of radioactive ribidiurn (86Rb +) was used to determine indirectly 
the Na+,K+ -ATPase pump function. 
Hypothesis #3 
Direct delivery of exogenous Mg-ATP preserves vascular endothelium viability 
in skeletal muscle during prolonged periods of warm ischemia, and this protection 
permits the reestablishment of normal blood flow during reperfusion allowing injured 
muscle to regenerate. 
To test hypothesis #3, a rat hind limb transplantation model was used. Five 
groups were included in this experiment. Using a modified Euro-Collins organ 
preservation solution (EC) in which dextrose was substituted with FL Vs loaded with 
10mM of Mg-ATP, we perfused isolated limbs from Wistar Furth rats every 4 hours 
for a total ischemic period of either 13 or 21 h. Amputated donor limbs were 
incubated at room temperature (23°C) in EC without dextrose (13 h), EC with empty 
FLVs (13 h), EC with free Mg-ATP without FLVs (13 h), and EC with Mg-ATP loaded 
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FLVs (13 and 21 h). After ischemic incubation, we transplanted the limbs to 
syngeneic recipients to avoid an immune response and rHjection, and followed the 
animals for up to 8 days. Skin and limb viability were assessed visually. Extensor 
Digitorum Longus (EDL) and soleus (SOL) muscles were harvested at the end of the 
study and histologically scored using the MALPH-3 index" 
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CHAPTER 2 
DELIVERY OF EXOGENOUS Mg-ATP PRESERVES NA+,K+-
ATPase PUMP FUNCTION DURING CHEMICAL HYPOXIA 
Introduction 
I/R injury is recognized as a serious problem that occurs in a variety of medical 
procedures including thrombolytic therapy, organ transplantation, vascular bypass 
surgery, trauma and reconstructive surgerl,67. I/R injury leads to post operative 
graft dysfunction and can contribute to delayed organ rejection. Endothelial cells 
have been shown to be a critical target of I/R injury.131-133 
I/R injury is a two step process.5 During ischemia, depletion of cellular energy 
storage, loss of cellular homeostasis and accumulation of metabolites lead to cell 
damage.3 This cellular damage can be further enhanced upon reperfusion by the 
production of oxygen radicals and chemotactic and inflammatory factors.4-7 
The maintenance of ionic homeostasis throughout active transport of ions 
across the cell membrane is crucial for the normal functioning and survival of the 
cells. As cells become hypoxic, energy storages become depleted and ionic 
homeostasis is lost.6 It is well known that the Na+,K+ ATPase is responsible for the 
maintenance of the Na+ gradient by the coupled movement of K+ and Na+ in and out 
of the cell, respectively. When cells are deprived from oxygen for oxidative 
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phosphorylation, intracellular levels of ATP gradually dwindle, and cause a decrease 
in ATPase activity, which also disrupts cell Na+/K+ balance and membrane potential. 
Maintenance of the Na+,K+ -ATPase pump activity during ischemia is crucial to the 
prevention of cell injury. 
Providing the cell with Mg-ATP as an exogenous source of energy during 
anoxia would be a rational approach to maintain Na+,K+-ATPase pump function and 
potentially prevent cell death. However, the problem with this apparently simple 
solution is that ATP does not readily diffuse across the cell membrane due to its 
hydrophilic characteristics. Nevertheless, investigators have tried using exogenous 
ATP in conjunction with organ preservation solutions with controversial 
results 102,105,108 and the concept has not gained widespread acceptance because 
adequate quantities of exogenous ATP will not diffuse into cells. To overcome this 
limitation, our group recently developed FLVs that rapidly deliver Mg-ATP into cells. 
Thus we hypothesized that by delivering Mg-ATP directly into endothelial cells, 
cell viability and Na+,K+-ATPase pump function would be maintained when the cells 
are exposed to chemical hypoxia. 
In this work, dose response studies were performed to optimize Mg-ATP 
delivery to HUVECs, and the efficacy of Mg-ATP delivery was determined by 
quantifying cell viability and ouabain-sensitive Na+,K+ -ATPase pump function 
following chemical hypoxia. Chemical hypoxia was induced using KCN, and cells 
were incubated in media devoid of any metabolically functional sugars to minimize 
endogenous production of ATP. The uptake of radioactive rubidium (86Rb+), a K+ ion 
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substitute, was used to measure Na+,K+ -ATPase pump function. Cell viability was 
assessed using a dye exclusion technique. 
Material and methods 
All experiments were conducted in cultured Human Umbilical Vein Endothelial 
Cells (HUVECs) and hypoxia was induced chemically by exposing the cells to KCN 
for 4 hours. Prior to the hypoxia experiments we determined the KCN concentration 
required to achieve complete loss of viability of cultured HUCECs after 4 hours of 
incubation. This experiment provided us with a standardized model of chemical 
hypoxia that was used in the cell viability studies. 
In a 24-well plate, HUVECs were seeded at a concentration of Sx1 03 cells/cm2. 
Cells were allowed to reach 30-40% confluence (3-4 days) and the plate was divided 
in 4 groups of 6 wells each. The control group was treated with 1.Sml of Krebs 
solution (without glucose) alone (no KCN). The remaining 3 groups were treated 
with 1.Sml of Krebs solution containing KCN at one of the following concentrations: 
2.S, S.O and 10 mM. The plate was then incubated at room temperature for 4 hours, 
washed three times with HBSS, labeled with SYTOX Green and SYTO 64 dyes and 
fixed with 4% glutaraldehyde. Cells were counted in 10 randomly selected 
observation fields to determine percent viability. 
Cell Culture 
Cryopreserved HUVECs were purchased from Cambrex Bio Science 
(Walkersville, MD). Cells were seeded at a density of SOOO cells/cm2 and incubated 
at 37°C with Endothelial Basal Medium-2 growth media (Cambrex Bio Science) 
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containing and the following supplements: Hydrocortisone, hFGF-B, VEGF, R1-IGF-
1, Ascorbic Acid, Heparin, FBS, hEGF, GA-1000 (Gentamcin, Amphotericin-B). 
Media was replaced the day after seeding and every other day there after. Dose 
response experiments were performed when cells reached 30 to 40% confluence (2-
4 days), and 86Rb+ uptake experiments were performed when cells reached 100% 
confluence (5-9 days). 
FL V Preparation 
FLVs were prepared using a modification of the dry film method134.135. Briefly, 
1 ,2-Dioleyol-sn-Glycero-3-Phosphocholine (DOPC), and 1-palmitoyl-2-0Ieyol-sn-
Glycero-3-phosphate (PaPA) were mixed together in chloroform at a ratio of 50:1 
(mol/mol). The chloroform was then removed from the lipid material by exposure to 
a tream nitrogen gas. The lipid film was vacuum pumped for a period of 12 hours to 
remove traces of chloroform. The lipid material was hydrated in Hanks Balanced 
Salt Solution (HBSS) to a concentration of 25 mg/ml. Mg-ATP (1 mM) was mixed the 
buffer and lipid. Then, this mixture was vortexed for a period of 1 min to create 
multilamellar vesicles and placed in a 37°C bath for 5 minutes. This was repeated 6 
times. The multi lamellar vesicles were placed in an ice bath and sonicated with a 
pulse sonication (40% duty cycle) for a period of 1 minlml to produce small FL Vs. 
The FLV solution was briefly centrifuged to remove traces of titanium from the 
sonicator probe. The diameter of the vesicles was measured using a Proterion 
DynaPro LSD Particle Size Analyzer (Proterion Corp., Piscataway, NJ) to insure that 
vesicle size was uniform throughout the study. The diameter of FLVs used in this study 
ranged between 220 and 380 nm. 
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Cell Viability Assay 
HUVEC viability was assessed using SYTOX (green) and SYTO 64 (red) 
Nucleic Acid Stains (Molecular Probes, Eugene, OR). A diluted mixture of both dyes 
was prepared as per manufacturer instructions. Briefly, culture media in wells was 
removed and replaced with an equal amount of HEPES- Buffered saline solution (H-
BSS) containing: 135mM NaCI, 5mM KCI, 1 mM MgS04 , 1.8mM CaCI2 and 10mM 
HEPES (pH 7.4). Two IJL of each, SYTOX Green and SYTO 64 were added for 
every 1 ml of H-BSS needed (1 :500 dilution of each) and mixed thoroughly by 
vortexing. The H-BSS buffer was then removed and replaced with diluted dye 
mixture (350-500 IJL per well). After incubation for 15 min in the dark at room 
temperature, the dye solution was removed and the cells washed three times with 
fresh H-BSS. Freshly prepared 4% glutaraldehyde in H-BSS was added and 
incubated for 1 hour. Cells were observed using fluorescent microscopy equipped 
with filter sets for viewing both green (488 Abs/520 Em) and red (599 Abs/619 Em) 
fluorescence. The total number of cells and the number of dead cells were counted 
in 10 randomly selected observation fields per well. For each field, red cells (all 
cells) were counted first. Then, green cells were counted to determine the amount 
of dead cells. The values for all ten fields were summed and percent viability per 
well was calculated as dead cells per well/total cells in well x 100. Each well was 
considered n=1. Positive and negative control dishes were run simultaneously. 
Measurements of Ouabain-sensitive 86Rb+ Uptake in HUVECs 
Na+,K+ -ATPase pump activity was measured in confluent HUVECs as ouabain-
sensitive 86Rb + uptake, using a similar method as previously described by McKenna 
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et al. 136 Uptake was measured in Hank's balanced salt solution without glucose 
(HBSS) containing (mM): NaC1140, KCI5, MgCb 1, CaCb 2, and HEPES 10 (pH 
7.4) at 3rC. Cells were preincubated for a specified period in HBSS containing 
KCN and various doses of Mg-ATP-Ioaded FUVs. To determine the ouabain-
sensitive 86Rb+ uptake, cells were incubated for 10 min with 100 IJM ouabain, 
followed by 30 min of incubation with -0.5 IJCi/mL 86Rb+. At the end of the uptake 
period, cells were washed six times in 1 ml ice-cold wash buffer. The wash buffer 
consisted of HBSS containing RbCI instead of KCI in order to displace 86Rb + from 
extracellular sites. Cells were solubilized in Lowry reagent and total cellular protein 
measured by the Lowry method (Sigma protein assay kit P5656). Radioactivitywas 
measured by liquid scintillation counting. Ouabain-sensitive uptake was calculated 
as the difference in uptake in the presence and absence of ouabain. 
Statistical considerations 
All results are expressed as mean ± standard error of the mean (SEM). 
Statistical analyses were performed using SPSS software (Statistical Package for 
the Social Sciences, version 14) and GraphPad Prism (version 4 for Windows). For 
comparison between groups, means were analyzed using univariate analysis of 
variance (ANOVA). Levene's Test for equality of variance was performed along with 
the ANOVA. A multiple comparisons (Games-Howell) test for unequal variances 
was selected as ANOVA post-hoc statistics. Unless otherwise specified, a 
probability level of p<0.01 was taken to indicate statistical significance. For 
experiment 3, the positive control and experimental group were compared using an 
independent-sample T-Test at the 0.05 level. 
45 
Experimental Design 
Experiment 1. Optimal dose of Mg-A TP 
This experiment was performed to determine the optimal dose of Mg-ATP that 
would maximize cell viability after chemical hypoxia. Cultured HUVECs were 
seeded in wells at a concentration of 5,000 cells/cm2 and allowed to reach 30-40% 
confluence (3-4 days). In the experimental groups, HUVECs were incubated with 
10mM KCN and Mg-ATP-Ioaded FLVs (3.08x1013 FLVs/mL) containing 2.5,5, or 10 
mM of Mg-ATP. Two control groups were included. In the negative control group 
(maximum cell death), HUVECs were placed in Krebs solution (without glucose) at 
23°C containing 10mM KCN alone (no FLV). In the positive control group (minimum 
cell death), cells were maintained in their culture media during the incubation period 
(no KCN/no FLVs). Cells were labeled with SYTOX green and SYTO 64 as 
described above. Then, cells were counted in 10 randomly selected observation 
fields to determine percent viability. 
Experiment 2. Effects of Mg-A TP loaded FL Vs 
This experiment was performed to compare the effects of Mg-ATP-Ioaded 
FLVs and control solutions composed of either Krebs only, Mg-ATP (without FLVs) 
or FLVs (without Mg-ATP). HUVECs were seeded in wells at a concentration of 
5,000 cells/cm2 and allowed to reach 30-40% confluence (3-4 days). HUVECs were 
then placed in Krebs solution (without glucose) at 23°C and incubated in 10mM KCN 
with one of the following: 1) Krebs alone, 2) FLVs loaded with 10mM Mg-ATP at 
3.08x1015 FLVs/mL, 3) FLVs without Mg-ATP at 3.08x1015 FLVs/mL, or 4) HBSS 
with 10mM Mg-ATP. A positive control group consisting of cells incubated in Krebs 
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solution but without KCN was also included. Cells were labeled with SYTOX green 
and SYTO 64 dyes as previously described. Cells were counted in 10 randomly 
selected observation fields to determine percent viability. 
Experiment 3. Preservation of Na+,J<: -ATPase function 
This experiment was performed to determine if the optimal concentration of 
exogenous Mg-ATP-FLVs observed to maintain cell viability in the previous 
experiments was able to preserve the rate of the Na+,K+ -ATPase ion transporter 
during chemical hypoxia. HUVECs were seeded in wells at a concentration of 5,000 
cells/cm2 and allowed to incubate for 6-9 days until they reach confluence. HUVEC 
monolayers were then incubated at 23°C for 4 hours with Krebs solution or Krebs 
solution with one of the following: 1) 10mM Mg-ATP-Ioaded FLVs, 2) empty FLVs or 
3) 10mM Mg-ATP. To measure ouabain-sensitive 86Rb+ uptake (as a substitute for 
K+), HUVECs were incubated for 10 min prior to the end of each experiment with or 
without ouabain (100 IJM) and followed by a 30 min incubation with 86Rb+ (-0.5 
IJCi/mL). At the end of the uptake period, cells were washed six times in 1 ml ice-
cold wash buffer. The wash buffer consisted of HBSS containing RbCI instead of KCI 
in order to displace 86Rb + from extracellular sites. Cells were lysed with 0.5M NaOH 
overnight at 4°C followed by standard colorimetric protein quantitation. A 
bicinchoninic acid (BCA) protein assay mixture (Pierce biotechnology, Rockford, IL) 
was prepared by combining reagents A and B (provided in kit) in a 50:1 ratio, 
respectively. 25-501JL of the cell lysate was added to 200IJL of BCA mixture, 
followed by incubation at 3JDC for 30 min. Absorbance was read at 562 nm. The 
levels of protein were then calculated from a standard curve generated with known 
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quantities of protein. Radioactivity was measured by liquid scintillation counting. 
Ouabain-sensitive uptake was calculated as the difference in uptake in the presence 
and absence of ouabain. 
Results 
Optimization of the Model 
To determine the concentration of KCN required to achieve complete loss of 
cell viability, 3 different concentrations (2.5, 5 and 10 mM) of KCN were tested. 
Control wells (no KCN) were incubated with Krebs solution without glucose. In the 
control group, 95.26±1.27% of the cells were viable after 4 hours of incubation. On 
the groups treated with KCN, a viability of 82.54%±0.48%, 65.50±4.26% and 
12.83±3.40% was observed for the wells treated with 2.5,5 and 10 mM of KCN, 
respectively (Figure 9). The one-way ANOVA_yielded a "p" value < 0.0001. On the 
post hoc multiple comparison, all groups showed a significant difference from 
controls (p<0.01). From this experiment, the 10mM concentration of KCN was 
selected to perform all subsequent experiments since it resulted in more than 87% 
cell death after 4 hours of incubation. 
Experiment 1: Optimal Mg-A TP loading of FL Vs 
To determine the ideal concentration of Mg-ATP that the vesicles needed to be 
loaded with to maintain cell viability after 4 hours of chemical hypoxia, three Mg-ATP 
concentrations (2.5, 5 and 1 OmM) were tested. The negative control group 
consisted of cells treated with Krebs solution (no FLVs). Only 16.2±2.64% were 
viable after 4 hours of chemical hypoxia. In the positive control group (no 
KNC/noFLV), 92.4%±1.25% were viable after 4 hours of incubation in culture media. 
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A concentration dependent effect on viability was observed in the experimental 
groups, in which 20±1.24%, 83±1.16% and 97±0.67% of the cells were viable after 
chemical hypoxia when treated with FLVs loaded with 2.5,5 and 10mM of Mg-ATP, 
respectively (Figure 10). The one way ANOVA showed a statistically significant 
difference between groups with a up" value <0.0001. A post hoc multiple comparison 
was performed to determine the difference between the experimental and control 
groups. When compared to the negative control, the 2.5mM Mg-ATP group showed 
a non-significant difference (p=0.678) while the 5 and 10mM Mg-ATP groups were 
significantly different from controls (p<0.0001). The opposite was observed when 
the experimental groups were compared to the positive control. A up" value <0.0001 
was obtained for the two lower concentration groups (2.5 and 5mM Mg-ATP) while 
the 10mM Mg-ATP group was not different from the positive control with a up" value 
of 0.026. Since 10mM Mg-ATP loaded FLVs showed the effect to maintain viability 
after 4 hours of chemical hypoxia to levels comparable to controls, this Mg-ATP 
concentration was chosen as the optimal loading concentration for FLVs for 
following experiments. 
Experiment 2: Mg-A TP loaded FL Vs vs. control solutions 
This experiment was performed to test the efficacy of 10mM Mg-ATP loaded 
FL Vs in preserving cell viability during exposure to 4 hours chemical hypoxia. The 
test solution was compared against Krebs only, 10mM Mg-ATP (without FLVs) or 
FLVs (without Mg-ATP). The positive control consisting of cells incubated with 
Krebs solution without KeN showed a cell survival of 95±1.12%. Ninety seven 
percent ± 0.67% of the cells incubated with 10mM Mg-ATP FLVs were viable after 4 
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hour of chemical hypoxia. For the control solution, the survival rates were 
19.82±3.19%, 10.50±8.78% and 0.81±0.37% for Krebs solution, Mg-ATP only and 
FLVs only, respectively (Figure 11). A one way ANOVA showed a statistically 
significant difference between groups with a "p" value <0.0001. A post hoc multiple 
comparison was performed to determine the difference between the experimental 
and control groups. A significance level of 0.01 was used. When compared to the 
positive control group, the 10mM Mg-ATP-FL V group showed a non significant 
statistical difference with a "p" value of 0.615. All three control groups showed 
statistically significant differences when compared to both the positive control and 
the 10Mm Mg-ATP FLVs group, yielding "p" values < 0.01. These results 
demonstrate that delivery of Mg-ATP using FLVs can maintain cell viability at levels 
comparable to non-hypoxic cells when treated cells are exposed to up to 4 hours of 
chemical hypoxia. 
Experiment 3: Mainteinance of Na +, J<: pump activity 
This experiment was designed to determine whether the delivery of Mg-ATP to 
HUVECs using FLVs could maintain the ouabain sensitive Na+,K+ -ATPase pump 
activity after 4 hours of chemical hypoxia. 86Rb+ uptake was used as an indicator of 
pump activity and is expressed as mmollmg protein/min. As in the viability 
experiments, the test solution, 10mM Mg-ATP loaded FLVs, was compared against 
Krebs solution without glucose, 10mM Mg-ATP (no FLVs) and FLVs only (no Mg-
ATP). A positive control consisting of Krebs solution with glucose was also included 
for comparison purposes. The rate of 86Rb+ uptake in the 10mM Mg-ATP FLV group 
of 5.46±1.34 mmol/mg prot/min was not significantly different (p=0.807) from that of 
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the positive control of 4.8±2.58 mmol/mg prot/min when compared using Student's t-
test (Figure 12). The rate of 86Rb + uptake of 4.8 mmol/mg prot/min obtained in our 
positive controls is very similar to that obtained by Kawai et al in rat brain capillary 
endothelial cells of 4.6 mmol/mg prot/min. 137 We were unable to measure the rate of 
86Rb + uptake in the group treated with FVLs due to loss of cell adherence to plate 
bottoms which caused cells to be lost during required experimental washes. 
Therefore, the data that was generated from this group was not reliable and it was 
not included in the statistical analysis. The rates of 86Rb+ uptake for the two 
remaining control groups were 1.31 ±0.41 and 1.11 ±0.40 mmol/mg prot/min for the 
Krebs only and Mg-ATP only groups respectively (Figure 12). A one-way ANOVA 
including the 10mM Mg-ATP FLVs, Krebs only and Mg-ATP only groups showed a 
statistically significant difference between groups with a "p" value of 0.011. The 
Games-Howell post hoc test showed that both control groups were different from 
1 OmM Mg-ATP FLVs (p<0.05). 
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Figure 9. Percent viability of HUVECs in response to increasing doses 
of KCN for 4 hours. *OmM KCN vs other KCN concentrations p<O.01 
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Figure 10. Percent viability of HUVECs after 4 hours of KCN 
treatment. Response to increasing doses of exogenous Mg-ATP-
vesicles. *Control vs Mg-ATP-vesicles p<O.0001. 
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Figure 11. Percent viability of HUVECs incubated with Krebs, free Mg-
ATP, vesicles only and Mg-ATP-vesicles and subjected to 4 hours of 
KCN treatment. *Mg-ATP-vesicles vs KCN treated controls (blue bars) 
p<O.01. # Mg-ATP-vesicles vs Normal controls (black bar) p=O.615 
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Figure 12. Results of 86Rb+ uptake experiments in HUVECs incubated 
in Krebs, free Mg-ATP and Mg-ATP-vesicles (10mM) and subjected to 
4 h of KCN. * Mg-ATP-vesicles vs KCN treated controls (blue bars) 
p<O.OS. # Mg-ATP-vesicles vs Normal controls (black bar) p=O.807. 
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Discussion 
This study performed herein examined the effects of direct delivery of Mg-ATP 
to endothelial cells using FL Vs. It was demonstrated that Mg-ATP-FLVs are 
effective in maintaining cell viability and the functionality of the Na+,K+ -ATPase pump 
when cells are exposed to chemical hypoxia. Potassium cyanide irreversibly inhibits 
the electron transport chain in the mitochondria by binding the iron atom of the 
enzyme cytochrome c oxidase.138,139 After cell respiration has been inhibited, ATP 
can still be produced from glucose through anaerobic glycolisis. Further, it has been 
shown that in certain cell types, blockage of the electron transport chain can 
enhance glucose transport across the plasma membrane as a compensatory 
mechanism. 14o To avoid this and to make sure that the only source of energy was 
the exogenous Mg-ATP, we removed all metabolically functional sugars from the 
culture media. 
The recovery of the parenchymal cells after an ischemic insult greatly depends 
on a patent, functioning microvasculature to restore an adequate blood supply to the 
ischemic region. Depletion of ATP during ischemia leads to cell damage 
characterized by structural changes and alterations of ionic homeostasis which in 
turn leads to loss of normal cell function and cell viability.6,141 
Structural changes such as alterations on the cytoskeleton will lead to loss of 
endothelial barrier function and increase of transendothelial permeability.142 
Disintegration of F-actin filaments and the subsequent alteration of the cytoskeletal 
structure which in turn leads to cell retraction, loss of cell-cell and cell-matrix 
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interactions and increase in paracellular macromolecular mobility have been 
observed in the renal microvascular endothelium exposed to ischemia. 143,144 
Further, these cytoskeletal changes have been demonstrated to be directly related 
to the levels of ATP depletion in vitro. 145,146. 
Intracellular accumulation of Na+ during ischemia is a major determinant of 
ischemia reperfusion injury. Imahashi et al.27 showed in the rat heart that 
intracellular Na+ was accumulated during ischemia and that the accumulation at the 
end of ischemia was related with the length of ischemia. In another study of 
potassium cyanide (KeN) poisoned rat heart, Kupriyanov et aI., showed that KCN 
infusion caused a decrease is phosphocreatinine and ATP and an increase in 
phophatidylinositol (Pi) and Na+. This suggests that inhibition of Na+,K+ -ATPase by 
Pi is responsible for intracellular Na+ accumulation, whereas loss of K+ is associated 
with inhibition of the Na+,K+ -ATPase as well as an activation of ATP-sensitive K+ 
channels and the K+-Iactate cotransporter. In rat hepatocytes, Carini et al. showed 
that Na+ overload is critical to the development of irreversible cell injury during 
ischemia because it leads to uncontrolled cell swelling. 147 They also showed that 
Na+ accumulation is due to an increased Na+ influx caused by the activation of the 
Na+/H+ exchanger and the Na+ -HCO-3 secondary to intracellular acidification and a 
decrease in the Na+,K+ -ATPase activity secondary to ATP depletion. 148 Also, 
blockade of the pump with ouabain inhibits its ATPase activity and prevents cells 
from maintaining their Na+,K+ balance, which will disrupt cell homeostasis.22 Na+ 
accumulation during ischemia induces contractile dysfunction, has a deleterious 
effect on energy metabolism 15,29,30 and results in Ca2+ overload during the initial 
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phase of reperfusion. 18,32,33 Ca2+ overload along with oxygen metabolite mediated 
damage and alteration of the arachidonic acid metabolism have been identified as 
central players in the development of no reflow phenomenon. Ca2+ overload will 
contribute to alteration of the cytoskeleton 11 and will abolish oxidative phophorylation 
and ATP production when taken by the mitochondria in an attempt to buffer the 
intracellular excess. 149,150 Oxygen-radical production and arachidonic acid 
metabolism are also dependant on the intracellular concentration of Ca2+. 
Augmented concentration of intracellular calcium activates a protease that converts 
xanthine dehydrogenase to xanthine oxidase 151 and, with the re-introduction of 
oxygen upon reperfusion, xanthine oxidase catalyzes the conversion of 
hypoxanthine to xanthine and uric acid producing a burst of superoxide radical 
formation.149 Phospholipase A2 will also be activated by the increased calcium 
concentration. Then Phospholipase A2 cleaves membrane phospholipids releasing 
arachidonic aCid,152 the precursor for prostaglandin and thromboxane 
production. 149,152 
Preservation of the endothelium during ischemia is crucial for minimizing 
further damage upon reperfusion. All the above suggests that preservation of the 
Na+,K+ -ATPase activity is crucial for the maintenance of cell homeostasis during 
hypoxia. 
Current tissue preservation therapies do not deliver energy to the cells during 
ischemia in order to maintain cell viability. Instead, they attempt to slow down 
cellular metabolism by lowering the temperature, shut down ion transport systems by 
altering the concentration of ions in the preservation solutions or to counteract the 
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effects of reperfusion by administering free radical scavengers, antithrombotic 
agents or leukocytes and lipid peroxidation inhibitors before reperfusion.4 
Hypothermia extends viability of amputated limbs 153 and has been shown to improve 
survival of replanted limbs in human 154 and several animal models.155.156 However, 
muscle tissue is susceptible to cold ischemia reperfusion injury and this can be 
prevented by prior perfusion with a tissue preservation solution such as University of 
Wisconsin (UW) solution.157 Intra-arterial flushing with an organ preservation 
solution such as Euro-Collins and UW solutions is another treatment widely used for 
tissue preservation.4 UW solution has been reported to provide good endothelial 
protection for free flaps in humans. 158 Although these therapies have been proven 
successful, they still pose the limitation of cold storage that is not always available. 
In our study we demonstrated that, by directly delivering Mg-ATP into 
endothelial cells, their viability can be maintained after chemical hypoxia to levels 
comparable to those of normal controls. We also showed that, by delivering Mg-
ATP using FLVs to endothelial cells exposed to chemical hypoxia, the Na+,K+-
ATPase activity is sustained thus preventing loss of cell homeostasis. 
In conclusion, the experiments described in this chapter successfully tested the 
concept that direct intracellular energy delivery using fusogenic lipid vesicles 
sustains hypoxic cells. Although further development is needed to optimize the 
solution for in vivo use, the foundation is set for a new approach in the tissue 
preservation field. 
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CHAPTER 3 
PRESERVATION OF SKELETAL MUSCLE AT ROOM 
TEMPERATURE USING A DIRECT INTRACELLULAR MG-ATP 
DELIVERY SYSTEM 
Introduction 
The desire to reattach dismembered body parts or to transplant limbs to make 
people whole again has been recorded throughout the ages in holy legends. Saint 
Hippolytus was reported to have replanted the leg of an oxcart driver who had 
suffered the misfortune of losing his limb after a lightning strike. The 13th century 
legend of Saints Cosmas and Damian describes the transplantation of a leg from an 
unfortunate Moor to the stump site of a maimed Christian77. Although these ancient 
surgical feats were considered miracles and warranted sainthood, in today's medical 
practice, limb replantation is routinely performed and composite tissue 
transplantation (ie. hand and face transplantation) is gaining worldwide 
acceptance 159,160. In the United States, the need for grafts by people suffering from 
amputation secondary to any cause is currently estimated to be 1,285,000 per year. 
The National Center for Health Statistics has reported that 43,000 major limb 
amputations per year are performed in the United States alone. When limbs are 
traumatically severed, autologous tissue or prosthetic materials are used to 
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reconstruct the defect. Certainly, the best outcomes are achieved when native 
tissues are salvaged and supplemented with autologous tissue flaps transferred 
from adjacent or remote areas of the body. One of the challenges of salvaging 
amputated extremities is the mixture of tissues (skin, muscle, bone, nerves, etc) that 
comprise them and the differences in inherent tolerance to ischemia that each tissue 
type has. Skeletal muscle appears to be tolerant to ischemia for up to 4 hours, 
nerve changes remain reversible up to 8 hours, fat up to 13 hours, skin up to 24 
hours and bone up to 4 days77. It is widely accepted that the duration of ischemia 
correlates directly with the severity of the injury. However, it has been difficult in 
muscle to distinguish when muscle cells die because gross and microscopic 
changes are minimal for many hours following muscle death. 
When traumatic limb amputation only involves composite tissues that primarily 
contain skin, connective tissue, bone, and cartilage (e.g. hand digits), the "safe" 
warm ischemia window for re-attachment can be as long as 12 hours. However, 
when the amputation involves a large mass of skeletal muscle, depending on the 
duration of ischemia and ambient temperature, the patient is at risk of developing 
local compartment syndrome or systemic post-ischemia syndrome that can be lethal. 
Clinical cases have shown a correlation between the duration of limb ischemia and 
the incidence of severe systemic complications that are also associated with 
increased mortalitl2 • 
In the absence of oxygen during ischemia, the ATP needed to maintain cellular 
homeostasis is generated via anaerobic oxidation of glucose, which is highly 
inefficient and leads to lactic acid accumulation in skeletal muscle 161. When 
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ischemic limbs are replanted or reperfused after more than 4 hours of ischemia the 
"declamping phenomenon" is often observed systemically and is characterized by a 
large drop in blood pressure accompanied by a decline in total peripheral resistance. 
A compensatory increase in heart and respiratory rates follow, and as plasma 
continues to be sequestered within the ischemia damaged limb, severe 
hemoconcentration occurs throughout the body77. These events are also 
accompanied by a significant washout of potassium (K+) and acidic metabolites 161 
that circulate systemically. The resulting hyperkalemia, hemoconcentration, and 
acidosis can lead to shock syndrome in which cardiac output is reduced, cardiac 
arrhythmias are observed and eventually death may occur from ventricular 
fibrillation. 161 
Studies in ischemic muscle have demonstrated a close correlation between 
myonecrosis and depletion of ATP. Hayes et al. 78 reported that during ischemia, 
myocyte glycogen and creatine phosphate are preferentially depleted over ATP, and 
that until ATP was depleted little muscle necrosis occurred. In a similar study, 
Labbe et al.79 reported that the extent of necrosis in muscle after 3,4 and 5 hours of 
warm ischemia was 2,30, and 90%, respectively. Several preservation studies have 
shown that endothelial cells are a critical target of ischemia and their preservation is 
crucial in preventing 1/R.131 -'133 Here we hypothesize that direct delivery of 
exogenous Mg-ATP can preserve vascular endothelium viability in skeletal muscle 
during prolonged periods of warm ischemia, and this protection permits the 
reestablishment of normal blood flow during reperfusion allowing injured muscle to 
regenerate. 
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Materials and Methods 
Experimental groups 
Syngeneic Wistar Furth rats were used in the study as limb donors and 
recipients to avoid antigenic interference. Five groups were included in this 
experiment. Groups 1 to 3 (n=5, n=6 and n=5, respectively) were control groups and 
limbs were incubated for 13 hours at room temperature and perfused every 4 hours 
with a modified Euro-Collins (EC) containing free 1 mM of Mg-ATP (EC-Mg-ATP), EC 
only or EC with unloaded FLVs (EC-FLVs), respectively. Limbs from the 
experimental groups 4 and 5 (n=7 per group) were incubated at room temperature 
for 13 and 21 hours, respectively, and were perfused every 4 hours with EC 
containing 1 mM of Mg-ATP-Ioaded FLVs (Mg-ATP-FLVs). For composition of 
solutions see Table 2. 
Preparation of FL Vs 
To create FLVs containing Mg-ATP (Mg-ATP-FLV), the two phospholipids 
components, 1 ,2-Dioleyol-sn-Glycero-3-Phosphocholine (DOPC) and 1-Palmitoyl-2-
Oleyol-sn-Glycero-3-Phosphate (POPA) were mixed together in chloroform at a ratio 
of 50:1 (mol/mol). The chloroform was removed from the lipid material by exposure 
to nitrogen gas. The lipid film was vacuum pumped for a period of 12 hours to 
remove traces of choloroform. The lipid material was hydrated in EC solution 
(Baxter Health Corporation, Deerfield, IL) containing 1 mM of Mg-ATP to a 
concentration of 25 mg/ml. The buffer and lipid was vortexed for a period of 1 
minute to create multilamellar vesicles and placed in a 37°C bath for 5 minutes, and 
repeated 6 times. The multilamellar vesicles were placed in an ice bath and were 
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pulse sonicated (40% duty cycle) for a period of 5 minutes. The resultant small, 
fusogenic lipid vesicles were briefly centrifuged to remove traces of titanium from the 
sonicator probe. To create vesicles without Mg-ATP (EC-FLVs) the lipid material 
was hydrated with only EC and then processed as described above. For both 
solutions containing vesicles, a sample was taken after their preparation to measure 
the average hydrodynamic radius of the vesicles using a Proterion DynaPro LSD 
Particle Size Analyzer (Proterion Corp., Piscataway, NJ) to insure that vesicle size 
was uniform throughout the study. The diameter of FLVs used in this study ranged 
between 220 and 380 nm. Euro Collins (EC only) solution was perfused "as is" and 
1 mM Mg-ATP was added before the perfusion to the EC-Mg-ATP solution. 
Penicillin (Gibco, Invitrogen, MD) and Streptomicin (Gibco, Invitrogen, MD) at 
final concentrations of 200 U/mL and 200/-lg/mL, respectively, were added to all 
solutions after they were prepared. 
Hind-limb preservation and transplantation model 
Syngeneic Wistar Furth rats were used in the study as limb donors and 
recipients. Rats were housed in the animal research facility at the University of 
Louisville where they were kept in a controlled environment (humidity, temperature, 
12-hour light cycle, and air flow) and had unrestricted access to food and water. All 
procedures were conducted under inhalation anesthesia using 2-5% isoflourane 
(60mg/kg ip) mixed with oxygen. Animals were shaved and their skin was prepped 
for surgery with betadine and ethanol. Digital thermometers and adjustable heating 
pads were used during operations to maintain core body temperature between 36-
37°C. 
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Table 2. Composition of experimental solution used in the study. 
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Formulations 
Components Qty Units 
Euro-Collins Potassium 115 mEq/L 
Solution Sodium 10 mEq/L 
Phosphate (as HP04=) 85 mEq/L 
Phosphate (as HP04-) 15 mEq/L 
Cholride 15 mEq/L 
Bicarbonate 10 mEg/L 
Antibiotics Penicillin 200 U/mL 
Streptomycin 200 mg/mL 
ATP salt ATP-Magnesium chloride 1 mM 
Phospholipids 1,2-Dioleyol-sn-Glycero-3-Phosphocholine 25 mg/ml (DOPC) 
1-palmitoyl-2-oleoyl-sn-glycerol-3- 0.1 mg/ml phosphate (POPA) 
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Rats were euthanized with a lethal dose of sodium pentobarbital upon 
completion of the experimental protocol. All procedures in this study were 
performed in accordance with guidelines provided by the Animal Care and Use 
Committee of the University of Louisville School of Medicine, which conforms to the 
Guide for Care and Use of Laboratory Animals (Department of Health and Human 
Services, Publication No. [NIH] 86-23). 
Limb isolation procedure. 
A circumferential skin incision was made just proximal to the mid-thigh area. 
The femoral artery, vein and nerve were dissected and individual muscle groups of 
the hind limb were identified and divided as proximally as possible to their tendinous 
origins. Care was taken to not injure the profunda femoris vein. The sciatic nerve 
was identified, marked with a stay suture and sharply divided. The femur was 
exposed and divided transversely at the mid-shaft using a handle saw. Rats were 
anticoagulated with Heparin (50-100 U) injected intravenously into the contralateral 
femoral vein. After 5 min, the femoral artery was clamped as proximally as possible, 
divided and cannulated with a 24-gauge catheter. The femoral vein was also 
divided, as proximally as possible and cannulated (Figure 13). 
Limb perfusion procedure. 
After limbs were isolated, blood was flushed out by perfusing 40 ml of EC 
solution at a rate of 1 mLlmin using a syringe infusion pump. At the end of 1 hour of 
ischemia, limbs were perfused with 10 mL of either Mg-ATP-FL Vs or one of the 
three control solutions (EC only or EC-Mg-ATP or EC-FLVs) at a rate of 1 mLlmin. 
Isolated limbs were then placed in a sterile beaker containing the corresponding 
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perfusion solution. The limbs were placed inside an aseptic glass chamber, where 
the perfusion system had been set up, to protect it from contamination (Figure 14). 
Subsequent perfusions of 10 mL of the corresponding solution were performed 
every 4 hours and the total number of perfusions depended on the total time of 
incubation. Limbs incubated for 13 hours were perfused a total of 3 times while 
limbs incubated for 21 hours were perfused a total of 5 times. 
Limb transplantation procedure. 
The operative procedure to remove the native host limb was similar to the 
isolation procedure described above except that the recipient was not anticoagulated 
and all neurovascular structures were cut as distally as possible to allow for 
maximum length during the anastomosis of the transplanted limb. The femoral bone 
was fixed using a 2 mm Kirschner wire inserted intramedularly. Muscles and 
tendons were approximated using interrupted suture (5-0 Nylon). The femoral 
vessels and nerves were anastomosed using microsurgical technique (10-0 Nylon) 
and limbs were reperfused by releasing the arterial microsurgical clamps (Figure 
15). Skin was closed in layers using absorbable suture (5-0 Monocryl) and 
interrupted stitches. Recipients were returned to their cages where they were 
allowed to recover from anesthesia. For analgesia, ketoprofen (3-5 mg/kg: i.m.) was 
administered once a day over the first three days, and thereafter, as needed if 
animals displayed signs of distress. A solution (Butler@ bitter safe mist, Columbus, 
OH) was sprayed on transplanted limbs to prevent automutilation (chewing) of 
insensate limbs. 
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Figure 13. Limb isolation procedure. After the skin and muscle are cut, 
the femoral vein is divided as proximally as possible and cannulated 
(;:)rrow) 
73 
74 
Figure 14. Aseptic glass chamber used to protect the limbs from 
contamination during incubation and the perfusion system set up. 
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Figure 15. Anastomosis of vessels and limb reperfusion after clamp 
release. 
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Assessment of limb viability 
From immediately after reperfusion until the animals were euthanized, limbs 
were observed for macroscopic signs of reperfusion and animals were monitored for 
signs and symptoms of post-ischemia syndrome. Although, no standard criteria was 
generated to assess reperfusion and/or post-ischemia syndrome, a clinical 
assessment was made every time based on clinical observations. Signs of 
reperfusion (or lack thereof) included arterial and venous blood flow and muscle 
bleeding during limb reattachment, appearance of hyperemia or cyanosis of the skin, 
capillary perfusion in the nail beds, limb temperature, and swelling of limbs. To 
assess post-ischemia syndrome and the appearance of shock, the general health 
state of the animals (color of the skin, body temperature, heart and respiratory rates, 
responsiveness, etc) was closely monitored. 
As per the experimental design, animals were to be sacrificed 8 days after limb 
transplantation. In some cases, animals were euthanized before the stipulated 8 
days because the transplanted limb had become necrotic. The date of termination 
was recorded as the date of limb death which was used in the Kaplan-Meier survival 
analysis. 
Histological Analysis 
After animals were euthanized, the soleus and extensor digitorum longus 
(EDL) muscles were isolated and harvested for histological analysis. Muscles were 
fixed in 10% formalin and prepared for longitudinal and transverse sections stained 
with hematoxin and eosin (H&E). A pathologist in a blinded fashion scored muscle 
sections using the MALPH-3 system 1 (Table 3). In this scoring system the 
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watershed value [what was more normal than abnormal (above) and what was more 
abnormal than normal (below)] is 6.50. The maximum upper score is 10.0 and the 
minimum score is 0.5. 
Statistical considerations 
Statistical analyses were performed using SPSS software (Statistical Package 
for the Social Sciences, version 14) and GraphPad Prism (version 4 for Windows). 
Survival fractions were calculated using the product limit (Kaplan-Meier) method. 
Comparison of the survival curves was done using the Mantel-Cox (Log-rank) test. 
Histological scoring results are expressed as means ± standard error of the mean 
(SEM) where n = number of muscles per group. For comparison of different muscle 
types within each group, means were analyzed using an independent-sample T-
Test. For comparison between groups, means were analyzed using univariate 
analysis of variance (ANOVA). Levene's Test for equality of variance was 
performed along with the T-Test and ANOVA. A multiple comparisons (Games-
Howell) test for unequal variances was selected as ANOVA post-hoc statistics. 
Goodman and Kruskal tau correlation was used to test the correlation between the 
different solutions and each individual histological parameter from the nominal by 
nominal crosstabs. A probability level of p<0.05 was selected to indicate statistical 
significance. 
80 
Table 3. MALPH 3 Index1 
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MALPH-3 Index 
Criteria 
U2 = White cell infiltration 
U3 = Localization of the white cell 
infiltration 
U4 = Edema 
us = Absence of muscle fiber 
nuclei 
U6 = Color aberrations 
U7 = Fiber aberration and absent 
nuclei localization 
U8* = There is muscle fibrosis 
present 
U9 = Congestion/sludging 
U10 = Endothelium aberrations 
U11 = Extravasation of 
erythrocytes 
0 
No infiltration 
No infiltration 
No edema 
No absence 
No aberrations 
No 
aberration/absence 
No Fibrosis 
No 
congestion/sludging 
No aberrations 
No extravasation 
Formula 
Value's 
1 
Some infiltration 
Periphery of 
vessels 
Some E~dema 
Some absence 
Some 
aberrations 
In well defined 
areas 
< 25% of the 
section 
Congestion 
At least one 
observed 
Rare 
2 
Throughout the 
slide 
Not limited to 
periphery 
Much edema 
Complete areas 
without 
Many 
aberrations 
Troughout the 
slide 
> 25% of the 
section 
Siudging 
Frequent or 
massive 
M3 = 10 - (1/3 ((4xU2) + (O.5xU3) + (1.5xU4) + (2.5xU5) + (1.5xU6) + U7 + (U8*+2(or -2)) + (O.5xU9) + 
U10 + (1.5xU11))) 
* If U8 <0 then, add 2; if U8 = 0 then, subtract 2. 
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Results 
In this investigation, we sought to develop a pneservation solution that would 
minimize I/R injury to ischemic extremities by minimizing energy expenditure while at 
the same time providing exogenous ATP to cells during the prolonged warm 
ischemia (23°C). The effectiveness of the solution was tested in a rat hind limb 
transplantation model. Several analyses were used to determine the difference 
between limbs treated with our preservation solution for 13 or 21 hours and the 
control solutions. First, survival fractions for the diffBrent groups were calculated 
using Kaplan-Meier method and compared using the log-rank (Mantel-Cox) test; 
second, the histological MALPH-3 scores were compared by ANOVA and third, a 
more detailed analysis of the parameters used in the histological scoring was 
performed by cross tabulation of each parameter against all the solutions perfused. 
Survival 
The results showed that most control limbs became hyperemic, gradually 
turned cyanotic, and eventually lost viability within 4 days (Figure 16 A). In few 
instances, control limbs appeared viable at 8 days post-transplantation but the 
skeletal muscle was mostly necrotic. On the other hand, limbs treated with Mg-ATP-
FL Vs appeared viable and well perfused at 8 days post-transplantation (Figure 16 A) 
with the presence of areas of regeneration (Figure 16 8). A survival analysis of all 
groups (Figure 17) showed that limbs that were ischemic for 13h and treated with 
Mg-ATP-FLVs survived significantly longer than limbs treated with EC only 
(p=O.0377) or EC+free Mg-ATP (p=O.0051). Limbs Ithat were treated with Mg-ATP-
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FLVs for 21 h survived longer than limbs treated with EC-Mg-ATP (p=0.02). Limbs 
treated with FL Vs only survived significantly longer than limbs treated with EC+free 
Mg-ATP (p=0.0143), indicating that FLVs alone appHar to have some protective 
effect and that free Mg-ATP in EC is detrimental. 
Muscle Histology 
Soleus and extensor digitorum longus (EDL) were harvested from the limb at the 
time of death and scored by an independent pathologist in a blinded fashion using 
the MALPH-3 system. The number of muscles analyzed per group is smaller 
compared to the number of animals in each group because some muscles could not 
be recovered duo to either auto mutilation of limb by the animals or because the 
animals died overnight and were found the following morning. First, Soleus and EDL 
MALPH-3 scores (Table 4) were compared by t-test within each treatment group to 
investigate if there was a differential effect of the perfusion solutions on slow twitch 
and fast twitch muscle (Soleus and EDL respectively). No statistical difference was 
found between muscle types for any of the treatment groups (p > 0.05). Then, the 
scores for each group were compared by ANOVA within each muscle type. This 
showed no statistical difference between groups for either Soleus or EDL muscles (p 
= 0.69 and 0.62, respectively). Therefore, for each !~roup the scores from both 
muscle types were pooled together for any further analysis (Table 5). No statistical 
difference was found between the combined scores for each group when compared 
by ANOVA (p = 0.83). Although, the statistical analysis of the scores shows no 
difference between the control limbs and the limbs treated with Mg-ATP-FLVs, the 
clinical and macroscopic outcome was clearly better in the latter groups. 
84 
Figure 16. Clinical and pathological features of transplanted limbs 
preserved for 13 hours at 23 ac. a. Limb preserved with EC only (left) 
and with EC-Mg-ATP-FLVs (right), after 12 hours post-transplantation, 
notice the cyanotic appearance of the limb nDt receiving EC-Mg-ATP-
FL Vs. b. Representative longitudinal sections of soleus muscles (x200) 
from a normal limb (top), and from transplanted limbs with either EC-
Mg-ATP-FLVs (middle) or with EC only (bottom). At 8 days post-
transplantation, muscle sections from viable limbs treated with EC-Mg-
ATP-FLVs had densely cellularized areas in which myocytes were 
markedly shrunken and were surrounded by proliferating satellite cells 
(middle). Muscles not receiving EC-Mg-ATP-FLVs were necrotic; 
notice the absence of nuclei in myocytes (bottom). c. EC-Mg-ATP-
FL Vs treated muscle preserved for 13 hours and harvested at 8 days 
post-transplantation showed adjacent areas of necrosis and viable 
muscle undergoing regeneration. The magnified circles (x400) show a 
patent vessel in the area of regeneration (right) and a vessel with 
thrombus (left) in the area of necrosis. Notice the presence of viable 
endothelial cells in the patent vessel (arrow) and their complete 
absence in the vessel with thrombus (arrow). 
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Figure 17. Kaplan-Meier survival curves of transplanted limbs 
preserved for 13 hours and 21 hours. Limbs treated with EC+Mg-ATP-
FLVs (13h) survived longer than limbs treated with EC (p=0.0377) or 
with EC+free Mg-ATP (p=0.0051). However, limbs treated for 21h were 
only significantly different from limbs treated with EC+free Mg-ATP 
(0=0.02), 
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EC only 
EC-FLVs 
EC-MgATP 
EC-MgATP-FLVs 13h 
EC-MgATP-FLVs 21h 
Table 4. MALPH-3 scores for Soleus (SOL) and Extersor Digitorius 
Longus (EDL) muscles by group. 
89 
MALPH 3 score results 
M3 score 
Mean SEM N 
Group 
EC only 
EDL 5.604 .805 5 
SOL 3.640 .295 5 
EC-FLVs 
EDL 4.256 .250 2 
SOL 5.505 .000 2 
EC-MgATP 
EDL 6.115 .364 3 
SOL 4.894 1.391 3 
EC--MgATP-FLVs-13 
EDL 5.375 .669 6 
SOL 5.366 .487 6 
EC--MgATP-FL Vs-21 
EDL 4.572 .887 5 
SOL 5.038 1.591 5 
SEM Standard Error of the Mean 
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Table 5. Combined (SOL and EDL) MALPH-3 scores for each 
treatment group. 
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MALPH 3 score results 
M3 score 
Mean SEM N 
Group EC only 4.622 .520 10 
EC-FLVs 4.880 .375 4 
EC-MgATP 5.505 .699 6 
EC--MgATP-FL Vs-13 5.370 .395 12 
EC--MgATP-FLVs-21 4.805 .862 10 
SEM = Standard Error of the Mean 
92 
Endothelium protection 
The question of why the observed clinical outcome of the experimental limbs 
was much better than the controls remained unanswered (although there were no 
statistical differences in the histology of the experimental and control groups). In 
order to elucidate this, a separate analysis of each variable used to obtain the 
MALPH-3 score was performed. The analysis consisted in the cross tabulation and 
correlation test between each variable and the solutions used to perfused the limbs. 
Of the 10 variables analyzed, only two showed statistical significance. First, the 
amount of cell infiltration was different between groups with a "p" value of 0.036. In 
the control groups, absence of or rare infiltration was more common compared with 
the experimental groups in which widespread cell infiltration was observed in about 
40% of the samples (Table 6). The second and most important variable that showed 
statistical significance was the presence of endothelium aberrations with p = 0.05. 
Clearly, both of the experimental groups had less endothelium aberrations than the 
controls. At least one aberration was observed only on 25% and 40% of the slides 
when the muscles were perfused with EC-Mg-ATP-FLVs for 13 and 21 hours, 
respectively. This is clearly different from the 70%,83.3% and 75% of slides when at 
least one aberration was observed for the CE only, CE Mg-ATP and CE-FLVs 
groups respectively (Table 7). This factor may very well explain the better clinical 
outcome observed in the two experimental groups. Also, these results suggest that 
Mg-ATP-Ioaded vesicles protected the vasculature to a greater extent than the 
muscle parenchyma itself. 
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Table 6. Cross-tabulation showing the percentage of cell infiltration for 
all the solutions tested. 
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Crosstab (Groups vs Cell Infiltration) 
Cell infiltration 
None Rare Widespread Total 
Group EC only Count 3 6 1 10 
% within Group 30.0% 60.0% 10.0% 100.0% 
EC-FLVs Count 0 4 0 4 
% within Group .0% 100.0% .0% 100.0% 
EC-MgATP Count 3 3 0 6 
% within Group 50.0% 50.0% .0% 100.0% 
EC--MgATP-FLVs-13 Count 6 5 12 
% within Group 50.0% 8.3% 41.7% 100.0% 
EC--MgATP-FLVs-21 Count 4 2 4 10 
% within Group 40.0% 20.0% 40.0% 100.0% 
Total Count 16 16 10 42 
% within Group 38.1% 38.1% 23.8% 100.0% 
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Table 7. Cross-tabulation showing the percentage of endothelium 
aberration for all the solutions tested. 
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Crosstab (Groups vs Endothelium Aberrations) 
Endotelium Aberrations 
At least 1 
None observed Total 
Group EC only Count 3 7 10 
% within Group 30.0% 70.0% 100.0% 
EC-FLVs Count 3 4 
% within Group 25.0% 75.0% 100.0% 
EC-MgATP Count 5 6 
% within Group 16.7% 83.3% 100.0% 
EC--MgATP-FL Vs-13 Count 9 3 12 
% within Group 75.0% 25.0% 100.0% 
EC--MgATP-FL Vs-21 Count 6 4 10 
% within Group 60.0% 40.0% 100.0% 
Total Count 20 22 42 
% within Group 47.6% 52.4% 100.0% 
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Discussion 
In ancient holy scriptures, the reattachment of an amputated limb by Saint 
Hippolytus,77 was considered miraculous and warranted sainthood. Today, this 
ancient surgical feat is a routine procedure, the success dependant on reducing 
tissue injury due to ischemia and reperfusion. Reduction of the duration of ischemia 
is the single most important factor in prevention of reperfusion injury. However, 
reduction of the ischemia time is not always possible and other measures are 
necessary to diminish the degree of ischemia and reperfusion injury. Hypothermia 
prolongs the viability of amputated limbs 153 and improves the survival of replanted 
limbs. 154 Intra-arterial flushing with organ preservation solutions such as University 
of Wisconsin and the EC solutions have also been used to minimize ischemia and 
reperfusion injury.158 Also, radical scavengers, anti-inflammatory modulators and 
lipid peroxidation inhibitors have been added to the preservation solutions to help 
reduce reperfusion injury.162,163 In situations where reanastomosis is planned to be 
made beyond the ischemia tolerance time for the flap, intra-arterial flushing with 
tissue preservation solutions and local hypothermia improve flap viability 
significantly.157 However, in many situations such as traumatic amputation of limbs, 
refrigeration is not practical or is not available and these limbs only benefit from a 
modest ATP sparing effect brought about by the cooling of limbs to ambient 
temperature. This creates a need for tissue preservation solutions that do not 
require hypothermia to exert their tissue preservation ability. 
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In this chapter, a rat limb transplantation model was used to test a method to 
reduce IR injury in amputated limbs when those limbs are kept a room temperature 
during the ischemia period. This method uses fusogenic lipid vesicles to directly 
deliver Mg-ATP inside the cell. This direct energy delivery method is a paradigm 
shift from current organ preservation strategies in which substrate is provided to 
cells for ATP synthesis and tissue temperature is lowered (-4°C) to decrease 
cellular metabolic rate and ATP usage. By directly providing Mg-ATP to cells in 
ischemic limbs, our method minimizes cellular utilization of glucose and oxygen and 
lessens the need for low temperature hypothermia. 
Skeletal muscle was a focus of the study over other limb tissues because it has 
the highest metabolic rate which makes it the most susceptible to IR injury.77.79 After 
more than 4 hours of ischemia, muscle sustains considerable damage, and upon 
reperfusion, releases toxic metabolites into the systemic circulation, which can have 
lethal consequences.76.77.164 The results of our study showed that control limbs 
preserved without the benefit of intracellular delivery of Mg-ATP became hyperemic, 
gradually turned cyanotic and eventually lost viability after reperfusion. In a few 
instances, the skin of control limbs remained viable up to 8 days post-
transplantation. However, the skeletal muscle of these limbs was completely 
necrotic. This result was not unexpected since skeletal muscle has the highest 
metabolic rate of all the limb tissues and is the most susceptible to ischemia-
reperfusion injury.76 At 8 days post-transplantation, skin and skeletal muscle were 
viable in 83% and 67% of the limbs perfused with Mg-ATP-FLVs for 13 and 21 
hours, respectively. Survival of limbs to 13 hours of warm ischemia is more than 
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double than what it was previously reported by Nishikawa et al.165 In their study, 
adipomusculocutaneous flaps exposed for 2 hours to warm ischemia survived. 
Flaps exposed to 4 hours partially survived but those exposed to more than 6 hours 
became completely necrotic. 
It was interesting to find that some portions of some muscles were not viable in 
our study. Nevertheless, the areas of muscle that were viable were in an active 
state of regeneration, suggesting that the nourishing blood flow after reperfusion 
continued, and in fact aided the differentiation process of surviving skeletal muscle 
satellite cells. Viable endothelial cells in blood vessels were found in areas 
surrounded by regenerating skeletal muscle fibers, where as in areas where the 
muscle was necrotic, the endothelial cells of vessels were not viable. Also, the 
amount of endothelial aberrations in both Mg-ATP-FLVs groups was less than that in 
the controls. 
In the EC only group, limbs were incubated and perfused with EC with no 
additives for 13 hours. After transplantation, these limbs were immediately 
hyperemic, gradually turned cyanotic and eventually blood flow in the nail beds was 
observed to stop (Fig 16 A). After calculating the MALPH-3 scores for both muscles, 
the mean value for soleus was 3.69±0.29 and for EDL was 5.60 ± 0.80 and were not 
statistically different (p=0.07). These scores reflect a moderate degree of 
histological abnormality consistent with the presence of thrombus or congestion in 
blood vessels and endothelial aberrations, and a marked absence of nuclei in 
myofibrils at a higher degree than in other groups (Fig 168). However, these results 
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indicate that EC solution had the same effect on the predominantly slow-twitch fiber 
soleus muscle and the predominantly fast-twitch EDL muscle. 
In the second group (EC-FLVs), limbs were incubated with EC and lipid 
vesicles without Mg-ATP for 13 hours. It was hypothesized that membrane pores 
formed during lipid vesicle fusion could hyperpolarize cells and protect energy 
reserves. However, the macroscopic outcome of these limbs was similar to the 
limbs receiving EC with no additives. The limbs during reperfusion were hyperemic, 
became cyanotic and ultimately blood flow stopped. The muscle histological 
analysis showed that the mean MALPH-3 index for the soleus was 5.50 ± 0.2 and for 
the EDL was 4.25 ± 0.24 (p=0.126). These scores also reflected a moderate level of 
histological abnormality similar to the muscles perfused with EC solution alone. The 
damage was similar between fast-twitch and slow-twitch muscle. 
In the third group (EC-Mg-ATP), limbs were incubated with EC solution 
containing 1 mM of Mg-ATP but no vesicles for 13 hours. This experiment tested 
the ability of Mg-ATP to diffuse inside cells of limb tissues and provide ATP-derived 
energy during ischemia. The macroscopic outcome of limbs was similar to the two 
experimental groups above. The muscle histological analysis showed that the mean 
MALPH-3 index for the soleus was 4.89 ± 1.39, and for the EDt was 6.11 ± 0.36 
(p=0.47). These scores also reflected a moderate degree of histological abnormality 
similar to the muscles perfused with EC alone. The damage was similar between 
fast-twitch and slow-twitch muscle. 
In the fourth group (EC-Mg-ATP-FLVs 13), limbs were incubated with EC 
solution containing vesicles loaded with 1 mM of Mg-ATP for 13 hours. It was 
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hypothesized that Mg-ATP-Ioaded vesicles would deliver Mg-ATP into the cytosol of 
cells in limb tissues, prevent the complete depletion of intracellular Mg-ATP levels, 
and maintain muscle cell homeostasis. The macroscopic outcome of these limbs 
was very different from the three control groups above. Only in one of seven 
transplanted limbs were venous thrombus observed and blood flow eventually 
stopped within an hour of reperfusion. However, in the six successful limbs, there 
were no signs of excessive hyperemia during early reperfusion, limbs were pinkish in 
color, they were well perfused and circulation of blood in exposed muscle and nail 
beds was apparent (Fig 16 A). Histological analysis of skeletal muscle showed that 
the mean MALPH-3 index for the soleus was 5.36 ± 0.48, and for the EDL was 5.37 
± 0.66 (p=0.991). Although, these scores are close to the scores for controls and it 
reflects a moderate degree of histological abnormality, the clinical outcome of the 
limbs in this group was particularly different and much better. Most blood vessels 
appeared normal and viable, the endothelium had few aberrations, and there was no 
evidence of thrombus or congestion in 5 out of the 6 successful limbs. As reflected 
by the mean MALPH-3 scores, the soleus and EDL muscles were viable. However, 
there were necrotic fibers present surrounded by considerable muscle fiber 
regeneration. The EC-Mg-ATP-FL Vs solution appeared to protect equally fast-twitch 
and slow-twitch muscles. 
In a fifth set of experiments, to test the preservation ability of EC-Mg-ATP-FLVs 
solution, the incubation period of limbs was extended to 21 hours. Similarly to the 
13-hour group, the macroscopic outcome of these limbs was very different from the 
control groups. Even after 21 hours of warm ischemia, in the majority of these limbs, 
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there were no signs of excessive hyperemia during early reperfusion, limbs were 
pinkish in color, they looked well perfused and circulation of blood in exposed 
muscle and nail beds was apparent. The mean MALPH-3 index for the soleus was 
5.03 ± 1.59, and for the EDL was 4.57 ± 0.88 (p=0.804). In the same way as with 
the 13-hour group, the scores are close to those of controls, reflecting a moderate 
degree of histological abnormality. However, in this group the clinical outcome was 
particularly different and most blood vessels appeared normal and viable, with the 
histological sections showing less endothelial aberrations (Table 7). Also, the limbs 
treated with Mg-ATP-FLVs showed an increased amount of cell infiltration (Figure 16 
B and Table 6). This may be explained by the fact that there was a patent 
circulation in these limbs allowing good blood flow that, althou~Jh it lead to increased 
cell infiltration, it also helped the muscle to regenerate. 
These results indicate that EC solution, lipid vesicles alone or EC-Mg-ATP do 
not provide a protective effect to skeletal muscle and blood vessels after prolonged 
ischemia and reperfusion. On the other hand, EC-Mg-ATP-FLVs solution appeared 
to protect the limbs for up to 21 hours of warm ischemia. 
In conclusion, the fusogenic lipid vesicles used in this study were effective in 
delivering Mg-ATP into cells in warm ischemic limbs. Endothelial cells of skeletal 
muscle vessels appeared to be protected along with skeletal muscle satellite cells in 
the parenchyma. Satellite cells appeared to be stimulated to regenerate new muscle 
tissue. Further optimization of ATP-FLVs for limb preservation is needed. This 
direct ATP delivery technique has the potential to be used in many clinical situations 
to combat ischemia. 
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CHAPTER 4 
CONCLUDING REMARKS 
This dissertation presents new information regarding the direct delivery of Mg-
ATP to ischemic muscle using small fusogenic lipid vesicles. The results presented 
here show evidence that direct intracellular delivery of energy in the form of Mg-ATP 
is feasible and provides the basis for further development of this technology. 
In our first set of experiments we demonstrated in vitro that by delivering Mg-
ATP to cultured HUVECS, that viability and Na+K+ -ATPase pump funtion can be 
maintained when these cells are exposed to chemical hypoxia. For these 
experiments the lipid vesicles and Mg-ATP concentration were optimized to provide 
protection against chemical hypoxia for up to 4 hours. Although, no attemps were 
made here to extend the protection beyond 4 hours, this could potentially be 
achieved by modifying the vesicles' lipid composition and Mg-ATP content. 
Engineering of vesicles to deliver Mg-ATP for extended periods of time may be 
possible. This could be solved by using mixed formulations of fast and slow 
fusogenic lipid vesicles. 
Technical limitations prevented us from characterizing the effects of exogenous 
Mg-ATP on intracellular pathways and structures. Further investigation of the effects 
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of Mg-ATP on cellular organelles, intracellular trafficking and on the cytoskeleton as 
well as the effect of vesicle fusion on the cellular membrane is needed. This 
knowledge will be crucial for further engineering and development of this technology. 
In our last series of experiments we showed that limbs subject to 13 and 21 
hours of warm ischemia survived longer when perfused with Mg-ATP FL Vs than 
when perfused with control preservation solutions. Although, we failed to 
demostratate statistical significant difference in the histological score, muscles 
perfused with Mg-ATP FL Vs had clearly less endothelial aberrations than controls. 
Also, muscles perfused with Mg-ATP FLVs showed signs of regeneration and 
increased cell infiltration suggesting that blood vessels were protected during 
ischemia, allowing good blood flow upon reperfusion. 
Preservation solutions used routinely in clinical practice have proven to be 
effective in preserving ischemic tissues for prolonged periods of time. One caviat is 
the need for cold storage to maximize their effect. In many clinical situations, rapid 
access to refrigeration, let alone more complex organ cooling devices, is very 
limited. In these situations a preservation solution that does not need cooling, such 
as Mg-ATP FLVs would be extremely useful. 
There is, indeed, much work to be done to optimize this technology. Although 
challenging, the lipid vesicles should be engineered to deliver Mg-ATP for longer 
periods of time to avoid the need for repeated perfusions. The mechanism involved 
in vesicle fusion and delivery of Mg-ATP should be further studied and a better 
understanding of the effects of direct energy delivery to tissues is crucial. 
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Francois, W.D. Ehringer, G. Anderson, L. Laurentin-Perez, S. Chien, C. 
124 
Maldonado. Presented at the Research! Louisville. Jewish Hospital 
Foundation, Louisville, KY, Nov 3-7, 2003. 
2004 Non-hypothermic preservation of composite tissue grafts using a novel 
direct intracellular ATP delivery system". F.V. Grossi, G. Perez-Abadia, C 
Francois, W.D. Ehringer, G. Anderson, L. Laurentin-Perez, S. Chien, C 
Maldonado. Presented at the Research! Louisville. Jewish Hospital 
Foundation, Louisville, KY, Nov 3-7, 2003. 
2004 Accelerated wound healing using a newly developed adenosine 
triphosphate (ATP) delivery system. Ehringer WD, Thomas C, Essick E, 
Grossi F, Chien S. Biophysical Journal 86 (1): 518A-518A Part 2 Suppl. S, 
Jan 2004. Presented at the Annual Biophysical Society Meeting, Baltimore, 
February 2004. 
2004 Direct delivery of ATP to skeltal muscle to combat hypoxia. Keith RJ, 
Grossi F, Chiang B, Su S, Maldonado C, Ehringer W. FASEB Journal 18 (4): 
A569-A570 Suppl. S, MAR 23 2004. Presented at Experimental Biology, 
Washington D.C April 2004. 
2004 Use of direct energy delivery system to accelerate wound healing. 
Thomas CM, Essick E, Grossi FV, Abadia-Perez G, Wolfe D, Chiang B, 
Rose B, Keith R, Su S, Ehringer WD FASEB Journal 18 (5): A941-A941 
Suppl. S, Mar 24 2004 Presented at Experimental Biology, Washington 
D.C April 2004. 
2004 Hemodynamic effects of exogenous ATP delivery. Wolfe D, Grossi F, 
Perez G, Ehringer W.FASEB Journal 18 (5): A1279-A1279 Suppl. S, Mar 24 
2004. Presented at Experimental Biology, Washington D.C April 2004. 
2003 Development of a Direct Cellular Energy Delivery System". L Laurentin-
Perez, WD Ehringer, C Maldonado, G Anderson, B Chiang, C Francois, G 
125 
Perez-Abadia, F Grossi, and S Chien. Presented at the 4th Annual MD3 
Conference, Louisville, Oct 30, 2003. 
2003 Accelerated wound healing using a newly developed adenosine 
triphosphate (ATP) delivery system". W.D. Ehringer, C. Thomas, E. 
Essick, F.V. Grossi, G. Perez-Abadia, C. Maldonado, S. Chien. Presented 
at the Research! Louisville. Jewish Hospital Foundation, Louisville, KY, Nov 3-
7,2003. 
2002 Development of a Direct Cellular Energy Delivery System. WD Ehringer, 
C Maldonado, G Anderson, B Chiang, C Francois, G Perez-Abadia, L 
Laurentin-Perez, F Grossi, and S Chien. Presented at the Research! 
Louisville. Jewish Hospital Foundation, Louisville, KY, Oct 30, 2002 
PEER-REVIEWED PUBLICATIONS 
1. Barker JH, Furr A, Cunningham M, Grossi F, Vasilic D, Storey B, Wiggins 0, 
Majzoub R, Vossen M, Brouha P, Maldonado C, Reynolds Cc, Francois C, 
Perez-Abadia G, Frank JM, Kon M, Banis JC Jr. Investigation of risk 
acceptance in facial transplantation. Plast Reconstr Surg. 2006 Sep;118(3):663-
70. 
2. Cottrell BL, Perez-Abadia G, Onifer SM, Magnuson DS, Burke DA, Grossi FV, 
Francois CG, Barker JH, Maldonado c.: Neurodegeneration in Composite 
Tissue Allografts: Effect of Low Dose FK506 and Mycophenolate Maofetil 
Immunotherapy. Plast Reconstr Surg. 2006 Sep;118(3):615-23; discussion 624-5 
3. Francois CG, Brouha PC, Laurentin-Perez LA, Perez-Abadia G, Grossi FV, 
Barker JH, Hewitt CW, Kon M, Ramsamooj R, Maldonado C.Vascularized 
lymph node transplantation induces graft-versus-host disease in chimeric 
hosts. Transplantation. 2006 May 27;81(10):1435-41. 
126 
4. Brouha P, Naidu D, Cunningham M, Furr A, Majzoub R, Grossi FV, Francois 
CG, Maldonado C, Banis JC, Martinez 5, Perez-Abadia G, Wiggins 0, Kon M, 
Barker JH .. Risk Acceptance in Composite Tissue Allotransplantation 
reconstructive procedures. Microsurgery. 2006;26(3):144-9; discussion 149-50. 
5. Majzoub RK, Cunningham M, Grossi F, Maldonado e, Banis Je, Barker JH. 
Investigation of Risk Acceptance in hand transplantation. J Hand Surg [Am]. 
2006 Feb;31(2):295-302. 
6. Thomas Harralson, M.s.; Federico V. Grossi, M.D.; Edwin E. Quan, M.D.; 
Taskin Tecimer, M.D.; Gustavo Perez-Abadia, M.D.; Gary Anderson, Ph.D.; 
John H. Barker, M.D., Ph.D., Claudio Maldonado, Ph.D.: Ischemic 
Preconditioning of Skeletal Muscle: Duration of Late-Phase Protection. Ann 
Plast Surg. 2005 Aug;55(2):216-222. 
7. Cunningham M, Majzoub R, Brouha PCR, Laurentin-Perez LA, Naidu D, 
Maldonado C, Banis Je, Grossi F, Frank JM, Barker JH. Risk Acceptance in 
composite tissue allotransplantation reconstructive procedures: Instrument 
design and validation. European TournaI of Trauma 2004, 30:12-6. 
8. Quan EE, Ramirez 5, Tecimer T, Grossi FV, Barker JH, Maldonado e. Late 
phase ischemic preconditioning in skeletal muscle: Is the phenomenon 
protective? Microsurgery 2004, 24 (2): 151-156. 
9. Wiggins OP, Barker JH, Martinez 5, Vossen M, Maldonado e, Grossi FV, 
Francois CG, Cunningham M, Perez-Abadia G, Kon M, Banis Je. On the 
ethics of facial transplantation research. American TournaI Of Bioethics 2004, 4 
(3): 1-12. 
10. Banis Je, Barker JH, Cunningham M, Francois CG, Furr A, Grossi F, Kon M, 
Maldonado e, Martinez 5, Perez-Abadia G, Vossen M, Wiggins OP Response 
to selected commentaries on the AJOB target article lion the ethics of facial 
transplantation research. American TournaI Of Bioethics 2004, 4 (3): W23-W31 
127 
FUNDING HISTORY 
2005 National Institute of Health 
STTR Phase I. "New Anti-complement Therapy to Reduce Reperfusion 
Injury" 
Principal Investigator: C Maldonado, PhD 
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